[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 225
1. Pallud J, Devaux B, Nataf F, Roux FX, Daumas-Duport C: [Spatial delimitation of low grade oligodendrogliomas]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):254-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spatial delimitation of low grade oligodendrogliomas].
  • [Transliterated title] Délimitation spatiale des oligodendrogliomes de bas grade.
  • Image-guided surgery is the central element of therapeutic management of low grade gliomas and consequently, a precise preoperative definition of their spatial extension is necessary.
  • The question of the present work is: do the imaging abnormalities delineate the real spatial development of low grade oligodendrogliomas?
  • Moreover, mathematical models and histological studies suggest that MRI does not indicate the actual spatial extension of low grade oligodendrogliomas.
  • This study focused on histological analysis of biopsy samples performed outside MRI imaging abnormalities in patients who harboured a low grade oligodendroglioma.
  • Thus, conventional imaging findings, including MRI on T2-weighted and FLAIR sequences, are not able to provide the real spatial development and boundaries of low grade oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Invasiveness. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy. Brain / pathology. Brain / surgery. Female. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiopharmaceuticals. Retrospective Studies. Technetium Tc 99m Sestamibi

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292169.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


2. Wu A, Aldape K, Lang FF: High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. J Neurooncol; 2010 Aug;99(1):57-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors.
  • It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.
  • In the context of this claim, we analyzed a series of insular oligodendroglial tumors in order to determine the frequency of 1p/19q co-deletion in tumors arising in this region.
  • Four (50%) of eight oligodendrogliomas and four (67%) of six oligoastrocytomas demonstrated 1p/19q co-deletions.
  • Seven of the eight tumors with co-deletion of 1p/19q were WHO grade II gliomas.
  • There were no statistical differences between tumors with 1p/19q co-deletion compared to those with 1p and/or 19q intact in terms of age, preoperative KPS, presenting symptoms, left versus right lateralization, tumor location (purely insular versus extension into frontal or temporal lobe), preoperative tumor size.
  • In contradistinction to previous reports, loss of 1p/19q occurs commonly in insular oligodendroglial tumors.
  • With respect to 1p/19q, insular gliomas do not appear to be distinct from gliomas arising elsewhere in the brain.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1891-7 [16986124.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):638-50 [11596959.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2622-6 [15197805.001]
  • [Cites] Brain Res Brain Res Rev. 1996 Oct;22(3):229-44 [8957561.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):87-93 [9525843.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurology. 2004 Dec 28;63(12):2360-2 [15623700.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):176-83; discussion 176-83 [15987586.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E15 [16398465.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):639-52 [17440165.001]
  • [Cites] Acta Neurobiol Exp (Wars). 2007;67(2):103-12 [17691218.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):293-8 [18345516.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86 [18617055.001]
  • [Cites] J Neurooncol. 2009 Jan;91(1):1-5 [18726074.001]
  • [Cites] J Neurosurg. 2010 Jan;112(1):1-9 [19612970.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • (PMID = 20035368.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115729-04; United States / NCI NIH HHS / CA / P50CA127001; United States / NCI NIH HHS / CA / R01 CA115729; United States / NCI NIH HHS / CA / P50 CA127001; United States / NCI NIH HHS / CA / R01 CA115729-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS172388; NLM/ PMC2891585
  •  go-up   go-down


3. Gresner SM, Rieske P, Wozniak K, Piaskowski S, Jaskolski DJ, Skowronski W, Golanska E, Sikorska B, Liberski PP: Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender. Clin Neuropathol; 2006 Jan-Feb;25(1):18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
  • BACKGROUND: Loss of heterozygosity (LOH) on 1p and 19q is observed in most oligodendroglial tumors.
  • PATIENTS AND METHODS: We reviewed 14 patients with oligodendroglial tumors (10 low-grade and 4 anaplastic oligodendroglioma) to evaluate the frequency of LOH on 1p, 10q and 19q and correlate it with tumor grade and patients' age and gender; 5 loci on 1p and 5 on 19q as well as 4 on 10q were analyzed for LOH using PCR techniques.
  • RESULTS: LOH on 1p together with 19q was detected in 6 tumors, 1 tumor showed deletion of 19q accompanied with deletion on 10q.
  • Grade II oligodendrogliomas predominated among younger patients (p < 0.01) while grade III oligodendrogliomas predominated among women (p < 0.005).
  • No association between LOH on 1p nor 19q and tumor grade or patients' gender was found.
  • CONCLUSION: Our study provides several clinically interesting findings and further supports the hypothesis of chromosome 1p and 19q involvement in the oligodendroglial cancerogenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosome Aberrations. DNA, Neoplasm / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Age Factors. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Sex Factors

  • Genetic Alliance. consumer health - Chromosome 10.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465770.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


Advertisement
4. Kondyli M, Gatzounis G, Kyritsis A, Varakis J, Assimakopoulou M: Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors. J Neurooncol; 2010 Nov;100(2):157-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors.
  • Phosphorylated (activated) forms of Janus Kinase 2 (pJAK-2) and STAT-5 transcription factor (pSTAT-5), which are preferentially expressed after binding of erythropoietin (Epo) to its receptor EpoR, are known to be implicated in the molecular mechanisms controlling brain development.
  • The purpose of this study was to investigate the expression of these proteins (pJAK-2, pSTAT-5, and EpoR) in human brain tumors compared with normal brain.
  • Using specific antibodies and immunohistochemistry on formalin-fixed, paraffin-embedded semi-serial tissue sections a total of 87 human brain tumors and samples from normal brain tissue were studied. pJAK-2/pSTAT-5 nuclear co-expression was detected in 39% of astrocytomas, 43% of oligodendrogliomas, 50% of ependymomas, and in all (100%) of the medulloblastomas examined.
  • Oligodendrogliomas and medulloblastomas were EpoR immunonegative.
  • Tumor vessels exhibited EpoR, pJAK-2, and pSTAT-5 immunoreactivity.
  • In normal brain tissue, EpoR immunoreactivity was detected in neurons and vessels whereas pSTAT-5 and pJAK-2 immunoreactivity was limited to some neurons and a few glial cells, respectively.
  • These results indicate the existence of ligand (other than Epo)-dependent or independent JAK-2 activation that leads to constitutive activation of STAT-5 in most human brain tumors.
  • Given the oncogenic potential of the JAK/STAT pathway, detection of different pJAK-2 and pSTAT-5 expression profiles between groups of tumors may reflect differences in the biological behavior of the various human brain tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. Janus Kinase 2 / biosynthesis. Receptors, Erythropoietin / biosynthesis. STAT5 Transcription Factor / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Gene Expression Profiling. Humans. Immunohistochemistry. Middle Aged. Phosphorylation. Signal Transduction / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2006 Jan 27;339(4):1021-8 [16337149.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1086:213-22 [17185518.001]
  • [Cites] J Biol Chem. 1997 Jul 11;272(28):17694-702 [9211920.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19936-47 [14996842.001]
  • [Cites] Trends Biochem Sci. 2000 Oct;25(10):496-502 [11050435.001]
  • [Cites] J Am Soc Nephrol. 1998 Nov;9(11):1998-2004 [9808085.001]
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:759-66 [10642538.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6763-71 [14583472.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):311-9 [17661350.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Oct;287(4):C981-91 [15189810.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):476-87 [19136931.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2381-7 [9703883.001]
  • [Cites] J Neurobiol. 2005 May;63(2):159-71 [15702476.001]
  • [Cites] Lab Invest. 2003 Oct;83(10 ):1477-87 [14563949.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):332-9 [16428469.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):27251-61 [15899890.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):719-28 [10974037.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1668-77 [19176400.001]
  • [Cites] Nature. 1993 Dec 9;366(6455):580-3 [7504784.001]
  • [Cites] Nature. 2001 Aug 9;412(6847):641-7 [11493922.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):19-23 [11395848.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5663-74 [16847321.001]
  • [Cites] J Histochem Cytochem. 1996 Jun;44(6):615-20 [8666746.001]
  • [Cites] Neuropathol Appl Neurobiol. 2007 Jun;33(3):299-307 [17493011.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Mol Cancer Res. 2007 Sep;5(9):891-7 [17855658.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] J Neurosurg. 2007 Feb;106(2):338-50 [17410721.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):145-54 [12138409.001]
  • [Cites] Neoplasia. 2005 May;7(5):537-43 [15967106.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4442-9 [15856028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):862-7 [15642952.001]
  • [Cites] Lancet. 2002 Jan 12;359(9301):96-7 [11809248.001]
  • [Cites] Science. 1997 Oct 17;278(5337):477-83 [9334309.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1511-9 [17873904.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 6;320(4):1087-95 [15249201.001]
  • [Cites] J Cereb Blood Flow Metab. 2002 May;22(5):503-14 [11973422.001]
  • [Cites] FEBS Lett. 1999 Dec 31;464(3):159-63 [10618497.001]
  • [Cites] Genome Biol. 2004;5(12):253 [15575979.001]
  • [Cites] Acta Paediatr Suppl. 2002;91(438):36-42 [12477263.001]
  • [Cites] Endocrinology. 1995 Sep;136(9):4092-8 [7649117.001]
  • [Cites] Endocrinology. 1996 Sep;137(9):4037-45 [8756581.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:18-30 [15591419.001]
  • [Cites] Neuropathol Appl Neurobiol. 2009 Dec;35(6):555-65 [19298633.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Mar;62(3):228-36 [12638727.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):405-10 [15141349.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):440-6 [10470819.001]
  • [Cites] Biochem J. 2005 Sep 1;390(Pt 2):427-36 [15918795.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):969-81 [12209679.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):17-23 [17143473.001]
  • [Cites] Nat Neurosci. 2005 May;8(5):616-25 [15852015.001]
  • [Cites] J Neurosci Res. 1998 Nov 1;54(3):320-30 [9819137.001]
  • [Cites] FASEB J. 2005 Feb;19(2):249-51 [15556972.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Neurosci Res. 2002 Dec;44(4):391-403 [12445627.001]
  • [Cites] Mol Endocrinol. 2007 Sep;21(9):2218-32 [17550976.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;874:262-8 [10415537.001]
  • (PMID = 20336349.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin; 0 / STAT5 Transcription Factor; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


5. Frenel JS, Botti M, Loussouarn D, Campone M: [Prognostic and predictive factors for gliomas in adults]. Bull Cancer; 2009 Apr;96(4):357-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Facteurs pronostiques et prédictifs de réponse des gliomes cérébraux de l'adulte.
  • Malignant gliomas are the most prevalent type of primary brain tumor in adults.
  • They are then classified according to their degree of malignancy into low-grade gliomas (I and II) and high-grade gliomas (III an IV) according to WHO classification.
  • Because patients with a same histologic diagnosis have variable outcomes, there is a need to develop better prognostic markers to predict tumor behaviour and response to therapy.
  • For patients with low-grade gliomas, several clinical parameters affect prognosis and therapeutic options: histological type, tumor measurements, young age, performance status.
  • For high-grade tumors, prognostic and predictive molecular markers have been identified.
  • The combined loss of 1p and 19q is strongly correlated with the oligodendroglial phenotype and is associated with both chemotherapeutic response and prolonged overall survival in anaplastic (grade III) oligodendrogliomas treated with PCV chemotherapy and probably with temozolomide.
  • [MeSH-major] Brain Neoplasms. Glioma
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / metabolism. Chromosome Deletion. Humans. PTEN Phosphohydrolase / metabolism. Predictive Value of Tests. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357011.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 52
  •  go-up   go-down


6. Tozer DJ, Jäger HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, Waldman AD: Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed; 2007 Feb;20(1):49-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficient histograms may predict low-grade glioma subtype.
  • The purpose of this work was to investigate whether apparent diffusion coefficient (ADC) histograms of untreated low-grade astrocytomas and oligodendrogliomas exhibit different characteristics due to their biological differences, and whether a diagnosis of tumour subtype can be made at presentation using the histogram alone, which, if possible, would have an impact on clinical practise.
  • Fifteen patients with astrocytoma (AC) [11 male (mean age +/- standard deviation) 40 +/- 11 years], nine with oligodendroglioma (OD) (four male, 45 +/- 13 years) and three with oligoastrocytoma (OA) (two male, 60 +/- 11 years) were recruited and diffusion-weighted images (b = 0 and 1000 s mm(-2)) were acquired every 6 months to date or until malignant transformation.
  • ADC histogram analysis may aid non-invasive sub-classification of low-grade glioma histological subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Glioma / pathology
  • [MeSH-minor] Adult. Aged. Astrocytoma / classification. Astrocytoma / pathology. Brain Diseases / pathology. Calcinosis / pathology. Cysts / pathology. Data Display. Discriminant Analysis. Disease Progression. Female. Humans. Male. Middle Aged. Oligodendroglioma / classification. Oligodendroglioma / pathology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986106.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Grant] United Kingdom / Multiple Sclerosis Society / / 748
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Nordfors K, Haapasalo J, Korja M, Niemelä A, Laine J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Haapasalo H: The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer; 2010;10:148
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
  • BACKGROUND: Medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumours (PNETs) are the most common highly aggressive paediatric brain tumours.
  • Our aim was to investigate whether carbonic anhydrases (CAs), enzymes commonly overexpressed in various tumours including glioblastomas and oligodendrogliomas, are present in MBs and PNETs, and whether their expression can be correlated with patient prognosis.
  • METHODS: We determined the expression of the tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a series of MB/PNET specimens (n = 39) using immunohistochemistry.
  • RESULTS: Endothelial CA II, cytoplasmic CA II, CA IX and CA XII were expressed in 49%, 73%, 23% and 11% of the tumours, respectively.
  • CA II was detected in the neovessel endothelium and the tumour cell cytoplasm.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carbonic Anhydrase II / analysis. Carbonic Anhydrases / analysis. Cerebellar Neoplasms / enzymology. Medulloblastoma / enzymology. Neuroectodermal Tumors, Primitive / enzymology. Supratentorial Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis. Chi-Square Distribution. Child. Child, Preschool. Cytoplasm / enzymology. Endothelial Cells / enzymology. Female. Finland. Humans. Immunohistochemistry. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Middle Aged. Odds Ratio. Proportional Hazards Models. Time Factors. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Hum Reprod. 2000 Jan;6(1):68-74 [10611263.001]
  • [Cites] BMC Cancer. 2008;8:1 [18173856.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 [10688890.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Dec;26(6):504-12 [11123716.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Bioorg Med Chem. 2001 Mar;9(3):703-14 [11310605.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Feb;12(2):283-7 [12556221.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • [Cites] J Histochem Cytochem. 1983 Jul;31(7):879-86 [6406590.001]
  • [Cites] Cancer Metastasis Rev. 1987;5(4):343-65 [2882864.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Histochemistry. 1993 Jan;99(1):37-41 [8468192.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Acta Neuropathol. 1994;88(6):520-6 [7879598.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):620-3 [8605096.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):896-9 [9500446.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13 [9636197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Nov-Dec;20(6):520-7 [9856671.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2158-61 [15538222.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):155-63 [15633208.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):458-75 [16041741.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8201-7 [16299253.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1055-62 [16294030.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):131-8 [18322268.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):395-400 [18464292.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27799-809 [18703501.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1319-23 [18485615.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):358-68 [19118021.001]
  • [Cites] Br J Neurosurg. 2009 Aug;23(4):364-75 [19637007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16233-8 [19805286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):246-54 [16618579.001]
  • [Cites] Neurol India. 2006 Mar;54(1):16-23 [16679637.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5190-200 [16707443.001]
  • [Cites] Acta Neuropathol. 2006 Jul;112(1):5-12 [16685513.001]
  • [Cites] BMC Dev Biol. 2006;6:22 [16719910.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):1025-33 [16964400.001]
  • [Cites] Adv Clin Chem. 2006;42:167-216 [17131627.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4109-17 [16931630.001]
  • [Cites] Histopathology. 2006 Dec;49(6):594-602 [17163844.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):308-13 [17435181.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):70-5 [17172824.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Cancer Immun. 2007;7:14 [17705350.001]
  • [Cites] Nat Rev Drug Discov. 2008 Feb;7(2):168-81 [18167490.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):577-84 [10666387.001]
  • (PMID = 20398423.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase XII
  • [Other-IDs] NLM/ PMC2874782
  •  go-up   go-down


8. White ML, Zhang Y, Smoker WR, Kirby PA, Hayakawa M, Sickels WJ, Ryken TC, Berbaum K: Fluid-attenuated inversion-recovery MR imaging in assessment of intracranial oligodendrogliomas. Comput Med Imaging Graph; 2005 Jun;29(4):279-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluid-attenuated inversion-recovery MR imaging in assessment of intracranial oligodendrogliomas.
  • This retrospective study consisted of 17 consecutive patients with oligodendrogliomas.
  • We qualitatively and quantitatively assessed the diagnostic value of fluid-attenuated inversion-recovery (FLAIR) images compared with T2-weighted fast spin-echo (FSE) images for evaluating intracranial oligodendrogliomas.
  • Qualitative evaluations of signal intensity, tumor conspicuity, definition of tumor margin, distinction between solid and cystic-like parts within tumor, and calcification were performed.
  • Quantitative criteria comparing FLAIR to T2-weighted FSE images included tumor-to-background contrast and contrast-to-noise ratio (CNR) and tumor-to-cerebrospinal fluid (CSF) contrast and CNR.
  • Our results demonstrate that the FLAIR sequence can replace the T2-weighted FSE sequence for evaluating oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Image Enhancement. Male. Middle Aged. Retrospective Studies. United States

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890255.001).
  • [ISSN] 0895-6111
  • [Journal-full-title] Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  • [ISO-abbreviation] Comput Med Imaging Graph
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H, Quinoñes-Hinojosa A: Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery; 2008 Oct;63(4):700-7; author reply 707-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
  • OBJECTIVE: It remains unknown whether the extent of surgical resection affects survival or disease progression in patients with supratentorial low-grade gliomas.
  • Our main outcome measures were OS, PFS, and malignant degeneration-free survival (conversion to high-grade glioma).
  • RESULTS: One hundred thirty-two primary and 38 revision resections were performed for low-grade astrocytomas (n = 93) or oligodendrogliomas (n = 77).
  • After GTR, NTR, and STR, median time to tumor progression was 7.0, 4.0, and 3.5 years, respectively.
  • CONCLUSION: GTR was associated with a delay in tumor progression and malignant degeneration as well as improved OS independent of age, degree of disability, histological subtype, or revision versus primary resection.
  • [MeSH-major] Astrocytoma / surgery. Neoplasm, Residual / diagnosis. Oligodendroglioma / surgery. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease Progression. Disease-Free Survival. Female. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neurosurgical Procedures. Proportional Hazards Models. Retrospective Studies. Survival Rate. Time Factors. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981880.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S: Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol; 2006 Dec;66(6):627-30; discussion 630-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report.
  • BACKGROUND: As in all diffuse gliomas, recurrence is an inherent feature of oligodendrogliomas, either as the same or higher grade neoplasm at the primary site.
  • The rate of remote recurrence after surgery for the primary tumor cannot be estimated from the scarce literature, but delayed treatment of the primary tumor and genetic alterations may be associated with this phenomenon.
  • A magnetic resonance imaging scan disclosed a right frontal mass lesion showing features of a low-grade glioma for which he refused any treatment.
  • Seven months after diagnosis upon uncontrollable seizures, he underwent a stereotactic biopsy, which was followed by a right frontal craniotomy, both of which confirmed the lesion as a grade 2 oligodendroglioma.
  • CONCLUSION: Recurrence of a frontal lobe oligodendroglioma remote from the primary site as a GBM is a rare occurrence.
  • As the genetic analysis suggests, conversion of oligodendroglioma to GBM may be associated with gain of chromosome 7, loss of chromosome 10, and other genetic markers that may represent late events in the oncogenesis of oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Monosomy / diagnosis. Monosomy / genetics. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Radiosurgery / instrumentation. Seizures / diagnosis. Seizures / etiology. Trisomy / diagnosis. Trisomy / genetics

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145331.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Pinto GR, Clara CA, Santos MJ, Almeida JR, Burbano RR, Rey JA, Casartelli C: Mutation analysis of gene PAX6 in human gliomas. Genet Mol Res; 2007;6(4):1019-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common tumors of the central nervous system.
  • Gene PAX6, which encodes a transcription factor that plays an important role in the development of the central nervous system, was recently recognized as a tumor suppressor in gliomas.
  • The objective of the present study was to analyze the mutational status of the coding and regulating regions of PAX6 in 94 gliomas: 81 astrocytomas (11 grade I, 23 grade II, 8 grade III, and 39 grade IV glioblastomas), 5 oligodendrogliomas (3 grade II, and 2 grade III), and 8 ependymomas (5 grade II, and 3 grade III).
  • Therefore, we conclude that the tumor suppressor role of PAX6, reported in previous studies on gliomas, is not due to mutation in its coding and regulating regions, suggesting the involvement of epigenetic mechanisms in the silencing of PAX6 in these tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Eye Proteins / genetics. Glioma / genetics. Homeodomain Proteins / genetics. Mutation. Paired Box Transcription Factors / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Base Sequence. Child. Child, Preschool. DNA Mutational Analysis. DNA Primers / genetics. DNA, Neoplasm / genetics. Ependymoma / genetics. Epigenesis, Genetic. Female. Gene Silencing. Humans. Infant. Male. Middle Aged. Oligodendroglioma / genetics. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273794.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins
  •  go-up   go-down


12. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
  • Diagnosis of oligodendroglioma from other clear cell neoplasms of central nervous system (CNS) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
  • Herein, we present a 44-year-old male patient who had a diagnosis of right parietal oligodendroglioma grade II in 1994 which recurred in 2002.
  • He presented with intratumoral hemorrhage and he underwent radical resection of tumor in 2003.
  • Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Chromosomal analysis revealed 1p/19q deletion, which led to the diagnosis ofanaplastic oligodendroglioma grade III.
  • Accurate diagnosis of oligodendroglioma is crucial due to recent advances and promises in its treatment.
  • Current diagnostic methods of oligodendroglial tumors are discussed in context of differentiating oligodendrogliomas from other clear cell neoplasms of CNS, especially from extraventricular neurocytomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


13. Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, Ducati A: Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol; 2007 May;31(5):760-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
  • The distribution of caveolae within the normal brain and in brain tumors is controversial.
  • In the present study, we describe the expression of caveolin-1 (cav-1) in 64 brain tumors of different grade, of either astroglial or oligodendroglial origin.
  • All studied astrocitomas of any grade (from II to IV) were cav-1 positive, displaying staining patterns and intensity specifically associated to the different tumor grades.
  • In anaplastic astrocytomas, a less intense membrane staining or a cytoplasmic dotlike immunoreactivity were present, the latter being almost the exclusive pattern observed in diffuse astrocitomas grade II.
  • In contrast to astroglial tumors, the striking totality of grade II oligodendrogliomas and the large majority of grade III were lacking cav-1 expression.
  • In conclusion, among astroglial tumors cav-1 expression varies in distribution, pattern, and intensity specifically according to tumor types and grades.
  • The association between tumor progression and a more structured membranous pattern of cav-1 expression could suggest the hypothesis of a neoplastic shift towards a mesenchymal phenotype, whose behavioral and biologic significance worth further studies.
  • Finally, the lack of cav-1 immunoreactivity in oligodendrogliomas suggests its concrete application as a useful diagnostic marker.
  • [MeSH-major] Astrocytes / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Caveolin 1 / metabolism. Glioblastoma / metabolism. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Cell Line, Tumor. Cell Separation. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Disease Progression. Flow Cytometry. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460461.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


14. Erb G, Elbayed K, Piotto M, Raya J, Neuville A, Mohr M, Maitrot D, Kehrli P, Namer IJ: Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn Reson Med; 2008 May;59(5):959-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward improved grading of malignancy in oligodendrogliomas using metabolomics.
  • In spite of having been the object of considerable attention, the histopathological grading of oligodendrogliomas is still controversial.
  • Therefore the metabolome of 34 human brain biopsies, histopathologically classified as low-grade (LGO, N = 10) and high-grade (HGO, N = 24) oligodendrogliomas, was studied using high-resolution magic angle spinning nuclear magnetic resonance spectroscopy (HRMAS NMR) and multivariate statistical analysis.
  • The statistical model was then used to study biopsy samples that were classified as intermediate oligodendrogliomas (N = 6) and glioblastomas (GBMs) (N = 30) by histopathology.
  • The results revealed a gradient of tumoral hypoxia increasing in the following direction: LGOs, intermediate oligodendrogliomas, HGOs, and GBMs.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioblastoma / metabolism. Glioblastoma / pathology. Magnetic Resonance Spectroscopy / methods. Neoplasm Staging / methods. Oligodendroglioma / metabolism. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Models, Statistical. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18429037.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol; 2008 Dec;116(6):597-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the IDH1 codon 132 mutation in brain tumors.
  • We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
  • A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%).
  • The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Mutation
  • [MeSH-minor] Astrocytoma / genetics. Astrocytoma / pathology. Base Sequence. DNA Mutational Analysis. Disease Progression. Gene Frequency. Glioblastoma / genetics. Glioblastoma / pathology. Glioma / etiology. Glioma / pathology. Humans. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985363.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


16. Järvelä S, Parkkila S, Bragge H, Kähkönen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H: Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer; 2008;8:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX in oligodendroglial brain tumors.
  • METHODS: This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed oligoastrocytomas).
  • In Cox multivariate analysis CA IX expression, patient age and histological component (pure oligodendroglioma vs. mixed oligoastrocytoma) showed independent prognostic values (p = 0.009, p = 0.003 and p = 0.022, respectively), CA IX positivity predicting poorer outcome.
  • CONCLUSION: CA IX was proved to be an independent prognostic indicator in oligodendroglial brain tumors, and it also correlates reversely with cell proliferation.
  • It may have a role in the biology of oligodendrogliomas, and most interestingly, as it is mainly expressed in tumor tissue, CA IX could serve as a target molecule for anticancer treatments.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism. Oligodendroglioma / enzymology
  • [MeSH-minor] Adult. Cell Proliferation. Follow-Up Studies. Humans. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6567-71 [15475445.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):398-408 [9024293.001]
  • [Cites] Cancer Res. 1982 May;42(5):1955-61 [7066906.001]
  • [Cites] Am J Med. 1991 Sep 30;91(3C):14S-22S [1928205.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Aug;16(4):261-8 [7524516.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):279-85 [9665489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1197-207 [15752902.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Nov 1;15(21):4872-6 [16165351.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1750-7 [11410516.001]
  • [Cites] Mol Hum Reprod. 2001 Jul;7(7):611-6 [11420383.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:421-55 [11441809.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):643-9 [11690711.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):29-37 [11804280.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1205-12 [11861405.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Apr;28(2):89-94 [11972795.001]
  • [Cites] Med Res Rev. 2003 Mar;23(2):146-89 [12500287.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):155-64 [12744469.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600-19 [12796054.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23 [14684331.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):995-1004 [15010840.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):869-73 [15012984.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • (PMID = 18173856.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2245965
  •  go-up   go-down


17. Kuo LT, Kuo KT, Lee MJ, Wei CC, Scaravilli F, Tsai JC, Tseng HM, Kuo MF, Tu YK: Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer; 2009 Jun 15;124(12):2872-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.
  • Recent studies have revealed a correlation between specific genetic changes, such as loss of chromosome 1p and 19q, and sensitivity of oligodendroglial neoplasm to radiotherapy and chemotherapy; epigenetic changes also play an important role in some tumors.
  • In this retrospective study, we analyzed chromosomal alterations in 17 loci and promoter methylation status of 8 tumor-related genes in 49 oligodendroglial tumors (29 WHO grade II and 11 WHO grade III oligodendrogliomas; 7 WHO grade II and 2 WHO grade III oligoastrocytomas) using quantitative microsatellite analysis and methylation-specific polymerase chain reaction and correlated this information with clinical data.
  • Our findings suggest that the frequent deletion and hypermethylation of tumor-related genes may represent a mechanism of tumor development and progression and emphasize the importance of defining new molecular markers for predicting prognosis, tumor recurrence and therapeutic response in cancer management.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human / genetics. Epigenesis, Genetic. Neoplasm Proteins / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. Child, Preschool. DNA Methylation. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / genetics. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Microsatellite Repeats. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Retrospective Studies. Survival Rate. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Ubiquitin-Protein Ligases / genetics. Ubiquitin-Protein Ligases / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • [ErratumIn] Int J Cancer. 2009 Sep 1;125(5):1241
  • (PMID = 19330828.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


18. Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT, Lim CC: Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery; 2005 May;56(5):919-26; discussion 919-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.
  • OBJECTIVE: Oligodendroglial tumors form an uncommon, but distinct, subgroup of gliomas with longer survival, better treatment response, and characteristic genetic alterations.
  • Noninvasive grading of oligodendroglial tumors using functional and metabolic magnetic resonance imaging may be helpful in guiding the treatment approach and predicting malignant transformation of these tumors.
  • We used perfusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopic imaging (MRSI) to predict the oligodendroglioma grade.
  • METHODS: Twenty-four patients with pathologically confirmed oligodendrogliomas underwent dynamic contrast-enhanced perfusion-weighted magnetic resonance imaging and/or proton MRSI before surgery.
  • We assessed the ability of tumor contrast enhancement, normalized cerebral blood volume, normalized choline, and the presence of either lactate or lipid metabolites to correctly predict the World Health Organization tumor grade.
  • The accuracy of tumor grading using each method was also compared.
  • RESULTS: Tumor contrast enhancement (P = 0.069) and normalized cerebral blood volume (P = 0.181) were not significantly different between low and high-grade oligodendrogliomas.
  • The MRSI measurement of normalized choline was significantly higher in high-grade (2.82 +/- 0.64) than in low-grade (1.62 +/- 0.46) oligodendrogliomas (P < 0.001), and the presence of lactate or lipid metabolites also correctly predicted high-grade tumors (P = 0.014).
  • The maximum accuracy of contrast enhancement, normalized cerebral blood volume, normalized choline, and lactate or lipid metabolites in grading oligodendroglioma was 71, 83, 90, and 85%, respectively.
  • CONCLUSION: MRSI measurements are more accurate than perfusion-weighted magnetic resonance imaging or conventional contrast enhancement in differentiating oligodendroglial tumor grade.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Observer Variation. Preoperative Care. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854239.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Ishizawa K, Komori T, Shimada S, Hirose T: Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol; 2008 May-Jun;27(3):118-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
  • In the neoplastic condition, Olig2 is widely expressed in astrocytomas and oligodendrogliomas, but its expression in ependymomas remains poorly documented.
  • A total of 59 brain tumors including 16 ependymomas, 32 astrocytomas, and 11 oligodendrogliomas were immunohistochemically studied for the expression of Olig2 as well as other markers including epithelial membrane antigen (EMA) and CD99.
  • In general, the Olig2-positive nuclei were only sparsely distributed in ependymomas; in contrast, they were very numerous in astrocytomas and oligodendrogliomas.
  • A quantitative study showed that the Olig2-positive nuclei were much fewer in ependymomas than in astrocytomas and oligodendrogliomas.
  • In our preliminary experiment, we noted the absence of CD99-immunoreactivity in a fraction of brain tumors with clear cell morphology, including oligodendroglioma, clear cell ependymoma, and pilocytic astrocytoma (the oligodendroglioma-like component).
  • Thus, we investigated the expression of CD99 in an additional series of brain tumors with clear cell morphology, including oligoastrocytoma (7 cases), central neurocytoma (6), and dysembryoplastic neuroepithelial tumor (9).
  • We found that the absence of CD99-immunoreactivity was dependent on clear cell morphology rather than on tumor entities.
  • The CD99-immunohistochemistry is unique in that it is helpful for the diagnosis of clear cell brain tumors through the visualization of CD99-negative clear cells.
  • [MeSH-major] Antigens, CD / genetics. Antigens, CD / metabolism. Basic Helix-Loop-Helix Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Cell Nucleus / chemistry. Child. Child, Preschool. Diagnosis, Computer-Assisted. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mucin-1 / analysis. Phenotype

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552083.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


20. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ: Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery; 2006 Jun;58(6):1099-107; discussion 1099-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
  • OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs.
  • METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
  • Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression.
  • Lesions with low baseline rCBV (< 1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (> 1.75) demonstrated progressively increasing tumor volumes over time.
  • CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Magnetic Resonance Imaging. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Volume. Cerebrovascular Circulation. Child. Child, Preschool. Disease Progression. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reference Standards. Survival Analysis. Treatment Outcome


21. Dutertre G, Levêque C, Delmas JM, Cordoliani YS, Nioche C: [Functional MR imaging and oligodendrogliomas]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional MR imaging and oligodendrogliomas].
  • The localization of functional areas obtained from functional MRI (fMRI) is useful for patients suffering from tumors contiguous to eloquent brain areas. fRMI is an efficient tool in the strategy of treatment of low grade oligodendroglioamas in the rolandic area in intact or slightly impaired patients.
  • Direct integration of fMRI data into neuronavigation enables to better visualize and preserve eloquent brain areas.
  • [MeSH-major] Brain Neoplasms / physiopathology. Magnetic Resonance Imaging. Motor Cortex / physiopathology. Oligodendroglioma / physiopathology
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Intraoperative Care. Neurosurgical Procedures. Preoperative Care. Temporal Lobe / physiopathology. Temporal Lobe / radionuclide imaging. Temporal Lobe / surgery. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292176.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol; 2007 Apr;14(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
  • Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed.
  • Several studies have reported the efficacy of various chemotherapeutic agents in a small number of patients with low-grade gliomas, e.g. pure astrocytomas, OG or mixed histologies.
  • We report the outcome of 33 consecutive patients with pure low-grade OG diagnosed between 1990 and 2006 systematically treated for residual or non-removable tumor with PCV chemotherapy regimen as the front-line treatment after surgery.
  • All the tumors were low grade (grade II) pure OG according to the WHO classification.
  • Response was evaluated by clinical assessment and brain magnetic resonance imaging.
  • Up-front chemotherapy with PCV regimen is a good treatment for symptomatic pure low-grade OG, as it increases the number of progression-free patients and time to progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Disease-Free Survival. Female. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388986.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


23. Kang HC, Kim IH, Eom KY, Kim JH, Jung HW: The role of radiotherapy in the treatment of newly diagnosed supratentorial low-grade oligodendrogliomas: comparative analysis with immediate radiotherapy versus surgery alone. Cancer Res Treat; 2009 Sep;41(3):132-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of radiotherapy in the treatment of newly diagnosed supratentorial low-grade oligodendrogliomas: comparative analysis with immediate radiotherapy versus surgery alone.
  • PURPOSE: The purpose of this study was to evaluate the role of immediate postoperative radiotherapy (RT) in adult patients with a low-grade oligodendroglioma (LODG).
  • All patients were closely observed until tumor progression or death with frequent work-ups including neurological examinations and MRI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1902-9 [10023313.001]
  • [Cites] Can J Neurol Sci. 1997 Nov;24(4):313-9 [9398978.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):567-73 [7928487.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4002-6 [8508366.001]
  • [Cites] Radiology. 1993 Feb;186(2):569-72 [8421767.001]
  • [Cites] Mayo Clin Proc. 1987 Jun;62(6):435-49 [2437411.001]
  • [Cites] J Neurosurg. 1988 May;68(5):684-8 [3357029.001]
  • [Cites] J Neurosurg. 1987 Aug;67(2):224-30 [3598683.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] Am J Clin Oncol. 2003 Jun;26(3):e60-6 [12796617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1405-9 [12459363.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):170-5 [10776979.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):797-802 [15936562.001]
  • (PMID = 19809562.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2757663
  • [Keywords] NOTNLM ; Brain neoplasms / Oligodendroglioma / Radiotherapy
  •  go-up   go-down


24. Pinto LW, Araújo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli LM, Soares FA: Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch; 2008 May;452(5):481-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis.
  • It has been demonstrated that a small percentage (approximately 15%) of glioblastomas (GBM) presents an oligodendroglial component with a variable frequency of chromosome 1p and 19q deletions, the genetic alteration related to chemotherapy response and longer survival in oligodendrogliomas.
  • A series of 88 GBMs was investigated regarding 1p and/or 19q losses, 24 with oligodendroglioma-like areas, using quantitative microsatellite analysis and/or fluorescent in situ hybridization.
  • When present, the oligodendroglial and astrocytic components were independently investigated.
  • Tumors with oligodendroglial components showed three cases each of 1p or 19q loss and one with combined 1p/19q loss.
  • No difference in 1p or 19q status was observed between the oligodendroglial and astrocytic components.
  • Deletions at 1p and/or 19q were infrequent in GBMs with oligodendroglial components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Gene Deletion. Glioblastoma / genetics. Glioblastoma / pathology. Oligodendroglia / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytes / pathology. Child. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Genotype. Humans. Kaplan-Meier Estimate. Male. Microsatellite Repeats / genetics. Middle Aged. Phenotype. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 [11939587.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4841-51 [14581356.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):242-51 [17284109.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):397-406 [17516742.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):311-20 [11355302.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]
  • [Cites] Histopathology. 2004 Jun;44(6):555-60 [15186270.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):971-81 [10963139.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):129-36 [17031656.001]
  • (PMID = 18351387.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


25. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • Intravascular thrombosis is a frequent finding in glioblastoma [GBM; World Health Organization (WHO) grade IV] specimens and could potentially be involved in astrocytoma progression to GBM or represent a surrogate marker of GBM histology.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).
  • Among newly diagnosed tumors, thrombosis was present in 92% of GBM resections, significantly greater than other types of CNS malignancies.
  • Thus, intravascular thrombosis is more frequent in GBM than other CNS malignancies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


26. Roerig P, Nessling M, Radlwimmer B, Joos S, Wrobel G, Schwaenen C, Reifenberger G, Lichter P: Molecular classification of human gliomas using matrix-based comparative genomic hybridization. Int J Cancer; 2005 Oct 20;117(1):95-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most frequent primary brain tumors and comprise a group of morphologically, biologically and clinically heterogeneous neoplasms.
  • The different glioma types are associated with distinct genetic aberrations, which may provide useful information for tumor classification as well as prediction of prognosis and response to therapy.
  • To facilitate the molecular classification of gliomas, we established a genomic microarray that consists of bacterial artificial chromosome (BAC) and P1-derived artificial chromosome (PAC) clones representing tumor suppressor genes, proto-oncogenes and chromosomal regions frequently gained or lost in gliomas.
  • Furthermore, molecular classification based on matrix CGH data closely paralleled histological classification and was able to distinguish with few exceptions between diffuse astrocytomas and oligodendrogliomas, anaplastic astrocytomas and anaplastic oligodendrogliomas, anaplastic oligodendrogliomas and glioblastomas, as well as primary and secondary glioblastomas.
  • [MeSH-major] Brain Neoplasms / classification. DNA, Neoplasm / analysis. Glioma / classification. Nucleic Acid Hybridization
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Mapping. Chromosomes, Artificial, Bacterial. Chromosomes, Human. Female. Gene Amplification. Genome, Human. Genomic Library. Humans. Male. Microarray Analysis. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15880582.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


27. Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ: Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res; 2009 Oct 15;15(20):6430-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
  • PURPOSE: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis.
  • EXPERIMENTAL DESIGN: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done.
  • In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and overall survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively).
  • Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048).
  • CONCLUSION: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):305-9 [10606174.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86 [18617055.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):16-25 [10918389.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4100-8 [12124348.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4760-3 [8062276.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1809-13 [8625052.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1107-13 [8780550.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):802-9 [15637687.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1246-52 [16525179.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):268-76 [16645215.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5010-6 [17311001.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • (PMID = 19808867.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057683-16; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / R01 CA057683-16
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS160000; NLM/ PMC2818514
  •  go-up   go-down


28. Erdamar S, Bagci P, Oz B, Dirican A: Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON; 2006 Apr-Jun;11(2):213-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Many characteristics of malignant brain tumors (increased vascular permeability, vasodilatation, neovascularisation and free radical injury to the tumor and adjacent normal tissues) are believed to be mediated by nitric oxide (NO) synthetized by endothelial NO synthase (eNOS).
  • Overexpression of vascular endothelial growth factor (VEGF) is associated with several central nervous system (CNS) diseases and tumors.
  • Our aim was to study immunohistochemically the coexpression of eNOS and VEGF in astrocytic tumors and to analyse their possible correlation with tumor grade, angiogenesis and proliferation index.
  • MATERIALS AND METHODS: Sections from 120 randomly selected patients with supratentorial astrocytic tumors [38 glioblastomas (GB), 22 anaplastic astrocytomas (AA) and 20 low-grade astrocytomas (LA)], also including oligodendrogliomas (n=20) and mixed oligoastrocytomas (n=20), were immunostained with monoclonal antibodies for eNOS and VEGF using the avidin-biotin method.
  • The proliferative potential was assessed as the MIB-1 staining index for tumor cells.
  • RESULTS: There was positive correlation between eNOS and VEGF expressions and histological grade (p<0.05) in terms of intensity and extent of immunoreactivity distribution.
  • Oligodendrogliomas showed significantly less VEGF and eNOS immunoreactivity compared to pure astrocytomas (p<0.05).
  • CONCLUSION: Overexpressions of eNOS and VEGF in astrocytic tumors were significantly correlated with histological grade, proliferative potential and malignant transformation.
  • The expression of VEGF in a necrotic and ischemic tumor such as GB is more intense and diffuse than low-grade astrocytomas.
  • These findings suggest that eNOS overexpression in tumor vasculature would be precipitated by transformation into an angiogenic phenotype in the process of neovascularisation in astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Nitric Oxide Synthase Type III / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Humans. Immunohistochemistry. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318973.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


29. Chawla S, Oleaga L, Wang S, Krejza J, Wolf RL, Woo JH, O'Rourke DM, Judy KD, Grady MS, Melhem ER, Poptani H: Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging; 2010 Jan;20(1):3-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas.
  • BACKGROUND AND PURPOSE: Preoperative differentiation of astrocytomas from oligodendrogliomas is clinically important, as oligodendrogliomas are more sensitive to chemotherapy.
  • The purpose of this study was to assess the role of proton magnetic resonance spectroscopy in distinguishing astrocytomas from oligodendrogliomas.
  • METHODS: Forty-six patients [astrocytomas (n= 17) and oligodendrogliomas (n= 29)] underwent magnetic resonance imaging and multi voxel proton magnetic resonance spectroscopic imaging before treatment.
  • The average metabolite/Cr ratios from these voxels were then compared between astrocytomas and oligodendrogliomas.
  • RESULTS: A significant difference in mI/Cr was observed between astrocytomas and oligodendrogliomas (.50 +/- .18 vs. 0.66 +/- 0.20, P < .05).
  • Using a threshold value of .56 for mI/Cr ratio, it was possible to differentiate oligodendrogliomas from astrocytomas with a sensitivity of 72.4% and specificity of 76.4%.
  • CONCLUSION: These results suggest that mI/Cr might aid in distinguishing oligodendrogliomas from astrocytomas.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Protons
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Brain / pathology. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. ROC Curve. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021846.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


30. Vyberg M, Ulhøi BP, Teglbjaerg PS: Neuronal features of oligodendrogliomas--an ultrastructural and immunohistochemical study. Histopathology; 2007 Jun;50(7):887-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal features of oligodendrogliomas--an ultrastructural and immunohistochemical study.
  • AIMS: To assess neuronal differentiation in oligodendrogliomas (ODGs).
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Central Nervous System Neoplasms / pathology. Neurons / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. DNA, Neoplasm / analysis. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Microscopy, Electron, Transmission. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543079.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


31. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L: Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging; 2005 Jan;32(1):39-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: 18F-fluorodeoxyglucose (FDG) and 11C-methionine (MET) PET imaging studies allow the investigation of metabolism and amino acid transport in brain tumours.
  • Their (relative) usefulness and prognostic value in suspected recurrence or progression of primary brain tumours after previous therapy is an issue of debate.
  • METHODS: Cerebral uptake of FDG and MET was determined sequentially on the same day in 30 patients (21 males, nine females; age 40.4+/-15.6 years), on average 4.0 years (range 0.1-18) after therapy for a primary brain tumour (23 grade II-IV astrocytomas, four oligodendrogliomas and three mixed oligo-astrocytomas).
  • CONCLUSION: FDG and MET PET studies provide complementary prognostic information in patients with suspected brain tumour recurrence or progression after primary therapy.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / mortality. Fluorodeoxyglucose F18. Glioma / diagnostic imaging. Glioma / mortality. Methionine. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Belgium / epidemiology. Child. Female. Humans. Male. Middle Aged. Observer Variation. Positron-Emission Tomography / methods. Positron-Emission Tomography / statistics & numerical data. Prevalence. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. Risk Assessment / methods. Risk Factors. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Sep 15;92 (6):1541-9 [11745233.001]
  • [Cites] J Nucl Med. 1995 Mar;36(3):484-92 [7884515.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Radiology. 2002 Nov;225(2):567-74 [12409596.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):608-15 [10682673.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):396-404 [11786566.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):542-50 [12507094.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Apr;16(2):187-98 [9101328.001]
  • [Cites] Neuroradiology. 2003 Jan;45(1):1-10 [12525947.001]
  • [Cites] J Appl Clin Med Phys. 2003 Winter;4(1):8-16 [12540814.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Pediatr Neurosurg. 2003 Mar;38(3):146-55 [12601239.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):165-74 [11303886.001]
  • [Cites] Neurology. 1996 Sep;47(3):684-90 [8797465.001]
  • [Cites] Acta Radiol. 1991 May;32(3):197-202 [2064862.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):23-7 [9443732.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] J Nucl Med. 1997 May;38(5):802-8 [9170450.001]
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12 ):1851-72 [11734927.001]
  • [Cites] J Neuroimaging. 1997 Jan;7(1):8-15 [9038426.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] N Engl J Med. 2001 Jun 28;344(26):2030-1 [11430342.001]
  • [Cites] Neurosurgery. 2002 May;50(5):958-64; discussion 964-5 [11950398.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):115-26 [8988735.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40 [11976801.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):855-61 [11504082.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;73(1-4):9-14 [10853090.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1098-106 [8780549.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):778-87 [10952489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54 [12377338.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1561-7 [14579097.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):205-12 [9935078.001]
  • [Cites] Radiographics. 1992 Mar;12 (2):269-79 [1561416.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] J Nucl Med. 1994 Jul;35(7):1104-9 [8014665.001]
  • (PMID = 15309329.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine
  •  go-up   go-down


32. Colin C, Virard I, Baeza N, Tchoghandjian A, Fernandez C, Bouvier C, Calisti A, Tong S, Durbec P, Figarella-Branger D: Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathol Appl Neurobiol; 2007 Aug;33(4):431-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to define specific markers for histogenesis of three well-characterized subgroups of human gliomas (pilocytic astrocytomas, glioblastoma multiforme and oligodendrogliomas), we studied the expression of relevant markers that characterize gliomagenesis, by immunohistochemistry and in situ hybridization.
  • Finally, in oligodendrogliomas, intermediate filament proteins are generally not observed whereas Olig2 was found in almost all tumour cells nuclei while only a subpopulation of tumour cells expressed Nkx2.2 and Sox10.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Intermediate Filaments / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Basic Helix-Loop-Helix Transcription Factors / genetics. Biomarkers, Tumor. Child. Child, Preschool. DNA-Binding Proteins / genetics. Glial Fibrillary Acidic Protein / biosynthesis. Glial Fibrillary Acidic Protein / genetics. High Mobility Group Proteins / genetics. Homeodomain Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Middle Aged. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics. Nestin. SOXE Transcription Factors. Vimentin / biosynthesis. Vimentin / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442061.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / High Mobility Group Proteins; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Nkx-2.2 homedomain protein; 0 / OLIG2 protein, human; 0 / SOX10 protein, human; 0 / SOXE Transcription Factors; 0 / Transcription Factors; 0 / Vimentin
  •  go-up   go-down


33. Liu JG, Liu YH, Cai J, Liu XS, Song WZ, Huang Y, Mao Q: [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):868-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors].
  • OBJECTIVE: To detect and analysis epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in different malignancy brain tumors, and to evaluate their prognostic significance.
  • METHODS: Using immunohistochemistry to detect the expression of EGFR and PTEN and adopting confocal technology to verify their location in the specimens of 25 respectively glioblastoma multiformes, medulloblastomas, anaplastic oligodendrogliomas, and anaplastic ependymomas.
  • However amplification of EGFR and deletion of PTEN were relatively low in other malignancy brain tumors.
  • They were 36% and 8% in medulloblastomas, and 28% and 8% in anaplastic oligodendrogliomas, and 24% and 4% in anaplastic ependymomas.
  • PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma, so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Young Adult


34. Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC: Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study. Neuropathol Appl Neurobiol; 2009 Aug;35(4):367-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
  • AIMS: The objective of the present study was to verify the correlation of chromosomes 1p and 19q status and expressions of O(6)-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization grades II and III.
  • METHODS: A series of 146 diffuse gliomas, including 45 oligodendrogliomas, 42 oligoastrocytomas and 59 astrocytomas, were analysed by denaturing high-performance liquid chromatography for 1p and 19q status and by immunohistochemistry for MGMT, p53 and Ki-67 expression patterns.
  • RESULTS: Loss of heterozygosity (LOH) on 1p, combined LOH on 1p and 19q, low MGMT expression and high Ki-67 expression were associated with oligodendroglial tumours, whereas high p53 expression was associated with astrocytic and mixed tumours.
  • LOH on 1p and low MGMT expression were associated with grade II oligodendroglial tumours, whereas high expressions of p53 and Ki-67 were associated with grade III oligodendroglial tumours.
  • In addition, high Ki-67 expression was associated with grade III astrocytomas.
  • LOH on 1p and LOH on 19q were associated with nontemporal oligodendroglial tumours.
  • CONCLUSIONS: The present study revealed significant interrelationships of the investigated molecular alterations and clinicopathological characteristics in diffuse gliomas of World Health Organization grades II and III, which support a promising role of molecular markers in the diagnostic assessment of these neoplasms.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Glioma / genetics. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Child. Female. Gene Expression. Humans. Loss of Heterozygosity. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / genetics. Oligodendroglioma / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019173.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


35. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer; 2006 Apr 15;106(8):1759-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
  • BACKGROUND: Loss of heterozygosity (LOH) on chromosomes 1p and 19q has been associated with chemosensitivity and improved prognosis in patients with oligodendrogliomas.
  • Recent studies demonstrated that temozolomide (TMZ), an oral alkylating agent, has efficacy in the treatment of patients with progressive, low-grade oligodendroglioma (LGO).
  • METHODS: Adult patients with magnetic resonance imaging (MRI) findings and/or clinical deterioration compatible with progressive LGO were eligible for the study if they were radiotherapy-naive.
  • Clinical and MRI data were used to evaluate outcomes, and Kaplan-Meier estimates were used to assess the median time to tumor progression (TTP).
  • The 1p/19q status was analyzed from paired tumor-blood DNA samples using polymerase chain reaction-based microsatellite analysis.
  • MGMT protein expression was estimated semiquantitatively by immunohistochemistry using paraffin embedded tumor sections.
  • RESULTS: There were 28 patients who received treatment, and the median time from diagnosis to tumor progression was 33.5 months.
  • The authors suggest the possible use of MGMT immunostaining as a surrogate marker for predicting tumor chemosensitivity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Loss of Heterozygosity. O(6)-Methylguanine-DNA Methyltransferase / analysis. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Repair. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16541434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


36. Juhász C, Chugani DC, Muzik O, Wu D, Sloan AE, Barger G, Watson C, Shah AK, Sood S, Ergun EL, Mangner TJ, Chakraborty PK, Kupsky WJ, Chugani HT: In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab; 2006 Mar;26(3):345-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors.
  • Abnormal metabolism of tryptophan has been implicated in modulation of tumor cell proliferation and immunoresistance. alpha-[(11)C]Methyl-L-tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo.
  • In the present study, we have measured tumor tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV).
  • All grade II to IV gliomas and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors.
  • Gadolinium enhancement on MRI was associated with high VD' values, suggesting impaired blood-brain barrier, while k(3)' values were not related to contrast enhancement.
  • Low-grade astrocytic gliomas showed increased tryptophan metabolism, as measured by k(3)'.
  • In contrast, oligodendrogliomas showed high VD' values but lower k(3)' as compared with normal cortex.
  • In astrocytic tumors, low grade was associated with high k(3)' and lower VD', while high-grade tumors showed the reverse pattern.
  • Increased AMT uptake can be due to increased metabolism of tryptophan and/or high volume of distribution, depending on tumor type and grade.
  • High tryptophan metabolic rates in low-grade tumors may indicate activation of the kynurenine pathway, a mechanism regulating tumor cell growth.
  • AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling tumor cell proliferation by acting on tryptophan metabolism.
  • [MeSH-major] Brain Neoplasms / metabolism. Cerebral Cortex / metabolism. Tryptophan / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Radioisotopes. Child. Child, Preschool. Electroencephalography / methods. Electroencephalography / standards. Female. Gadolinium. Glucose / metabolism. Humans. Infant. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Positron-Emission Tomography / standards. Seizures / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079785.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 13510-08-2 / alpha-methyltryptophan; 8DUH1N11BX / Tryptophan; AU0V1LM3JT / Gadolinium; IY9XDZ35W2 / Glucose
  •  go-up   go-down


37. Jenkinson MD, Smith TS, Joyce K, Fildes D, du Plessis DG, Warnke PC, Walker C: MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology; 2005 Jun 28;64(12):2085-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
  • BACKGROUND: Oligodendroglial neoplasms with combined loss of chromosomes 1p and 19q may have a good prognosis and respond to procarbazine-lomustine (CCNU)-vincristine (PCV) chemotherapy.
  • OBJECTIVE: To determine whether single voxel magnetic resonance spectroscopy (SV-MRS) obtained through routine clinical practice distinguishes between histopathologic and genetic subtypes of oligodendroglial tumors.
  • METHODS: Forty-eight patients with oligodendroglial tumors (19 oligodendrogliomas and 29 oligoastrocytomas) underwent molecular genetic analysis to determine allelic imbalance in chromosomes 1p36 and 19q13.
  • SV-MRS was obtained pretherapy to determine tumor metabolite ratios.
  • RESULTS: Grade III oligodendroglial tumors had higher choline (Mann-Whitney; p = 0.002), methyl lipid (Mann-Whitney; p = 0.002), and combined methylene lipid and lactate ratios (Mann-Whitney; p < 0.001) than grade II tumors.
  • Lactate did not distinguish between tumor types (Fisher exact test; p = 0.342) or grade (Fisher exact test; p = 0.452).
  • CONCLUSION: As a noninvasive diagnostic tool used in routine clinical practice, SV-MRS has the potential benefit of determining oligodendroglial tumor grade but not subtypes classified by histopathology or molecular genetics.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Magnetic Resonance Spectroscopy / standards. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adult. Aged. Allelic Imbalance / genetics. Choline / metabolism. DNA Mutational Analysis. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic / genetics. Genetic Testing. Genotype. Humans. Lactic Acid / metabolism. Lipids / analysis. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985578.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids; 33X04XA5AT / Lactic Acid; N91BDP6H0X / Choline
  •  go-up   go-down


38. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, Saltz JH, Brat DJ, Moreno CS: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One; 2010 Sep 03;5(9):e12548
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
  • Despite the richness of TCGA GBM data, the absence of lower grade gliomas in this data set prevents analysis genes related to progression and the uncovering of predictive signatures.
  • A complementary dataset exists in the form of the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt), which contains molecular and clinical data for diffuse gliomas across the full spectrum of histologic class and grade.
  • We demonstrate that the proneural signature predicts improved clinical outcome among 176 Rembrandt gliomas that includes all histologies and grades, including GBMs (log rank test p = 1.16e-6), but also among 75 grade II and grade III samples (p  =  2.65e-4).
  • This gene expression signature was enriched in tumors with oligodendroglioma histology and also predicted improved survival in this tumor type (n =  43, p  =  1.25e-4).
  • Thus, expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for lower grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.
  • Integrated DNA and RNA analysis of low-grade and high-grade proneural gliomas identified increased expression and gene amplification of several genes including GLIS3, TGFB2, TNC, AURKA, and VEGFA in proneural GBMs, with corresponding loss of DLL3 and HEY2.
  • This demonstrates that the expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for low-grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):567-73 [17250806.001]
  • [Cites] Bioinformatics. 2007 Dec 1;23(23):3251-3 [17644558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] BMC Genomics. 2007;8:461 [18088408.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Mol Cancer Res. 2009 Feb;7(2):157-67 [19208739.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2091-9 [19244127.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3468-76 [19617900.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):98-110 [20129251.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):837-49 [10879735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] EMBO J. 1988 Oct;7(10):2977-82 [2460335.001]
  • [Cites] Am J Physiol. 1995 Feb;268(2 Pt 1):L173-80 [7532367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1962 Mar;87:473-9 [13919885.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Bioinformatics. 2006 Jan 1;22(1):122-3 [16269418.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • (PMID = 20838435.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / PHS HHS / / S09-094; United States / NIBIB NIH HHS / EB / P20 EB000591; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NLM NIH HHS / LM / R01 LM011119
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2933229
  •  go-up   go-down


39. Schlierf B, Friedrich RP, Roerig P, Felsberg J, Reifenberger G, Wegner M: Expression of SoxE and SoxD genes in human gliomas. Neuropathol Appl Neurobiol; 2007 Dec;33(6):621-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Members of group E and group D of the Sox gene family function as important transcriptional regulators of glial development in the central nervous system.
  • SOX5, SOX9 and SOX10 were generally expressed at levels similar to or below those in adult brain tissue.
  • In contrast, many oligodendrogliomas exhibited upregulation of SOX6, SOX8 and SOX13.
  • Low-grade astrocytomas, but not glioblastomas, also showed elevated SOX8 transcript levels.
  • Taken together, the expression pattern of Sox genes in gliomas is heterogeneous and overall compatible with the less differentiated state of glioma cells as compared with their normal adult counterparts.
  • Despite their restricted expression in astrocytes and oligodendrocytes during normal development, none of the Sox genes was selectively expressed in tumours of the oligodendroglial or astrocytic lineage.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression. Glioma / metabolism. Sex-Determining Region Y Protein / biosynthesis
  • [MeSH-minor] Adult. Blotting, Western. Humans. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961134.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


40. Valera ET, Lucio-Eterovic AK, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Queiroz RG, Motta FJ, Tone LG: Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol; 2007 Oct;85(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system.
  • OBJECTIVES: To evaluate and compare the profile of expression of genes related to drug resistance in brain tumors and to analyze the impact of the increased expression of these genes on overall survival.
  • METHODS: Eighty microdissected brain tumor samples from 79 patients were analyzed by RQ-PCR for the genes MDR1, MRP1, MRP3, LRP and BCRP.
  • Pediatric cases (0 to 20 years): 46 (17F:29M, median age 7.3 +/- 5.9 years); adult tumors: 33 (17F:16M, median age 46.6 +/- 14.5 years).
  • Histological diagnoses: 21 astrocytomas I and II, 28 astrocytomas III and glioblastomas, 17 medulloblastomas, 8 ependymomas, and 6 oligodendrogliomas.
  • Low-grade astrocytomas expressed high MDR1 (P = 0.001), MRP3 (P = 0.01) and LRP (P = 0.02) levels.
  • The increased expression of resistance genes had no impact on the overall survival of patients with medulloblastomas/PNET and high grade gliomas.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / physiology. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Brain Neoplasms / mortality. Calibration. Child. Child, Preschool. DNA Primers. Female. Gene Expression Profiling. Glioma / drug therapy. Glioma / genetics. Glioma / mortality. Humans. Immunohistochemistry. Infant. Male. Medulloblastoma / drug therapy. Medulloblastoma / genetics. Medulloblastoma / mortality. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Survival Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):219-34 [16518375.001]
  • [Cites] Clin Neuropathol. 2004 Sep-Oct;23(5):223-31 [15581025.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] Clin Chem. 2002 Jun;48(6 Pt 1):811-7 [12028995.001]
  • [Cites] Pediatr Neurosurg. 1995;23(6):283-91; discussion 291-2 [8743996.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):377-82 [11745417.001]
  • [Cites] Nat Struct Mol Biol. 2004 Oct;11(10):918-26 [15452563.001]
  • [Cites] Epilepsia. 2005 Jun;46(6):849-57 [15946326.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Anticancer Drugs. 1999 Nov;10(10):861-72 [10630353.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1263-8 [8883415.001]
  • [Cites] Acta Neuropathol. 1997 Dec;94(6):605-11 [9444363.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):62-6 [11391622.001]
  • [Cites] Br J Neurosurg. 1994;8(5):585-91 [7857540.001]
  • [Cites] Virchows Arch. 1994;425(2):133-8 [7952498.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):113-21 [16193381.001]
  • [Cites] J Neurosurg. 1990 Jan;72(1):96-101 [2294193.001]
  • [Cites] Biol Pharm Bull. 2002 Nov;25(11):1391-400 [12419946.001]
  • [Cites] An Acad Bras Cienc. 2001 Mar;73(1):57-69 [11246270.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):11-8 [9874181.001]
  • [Cites] J Cell Sci. 1993 Sep;106 ( Pt 1):23-9 [8270627.001]
  • [Cites] Pediatr Pathol Lab Med. 1996 Jul-Aug;16(4):551-61 [9025853.001]
  • [Cites] Brain Tumor Pathol. 1999;16(1):23-7 [10532420.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98 (2):173-80 [11857404.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11419-28 [16357150.001]
  • [Cites] Curr Drug Deliv. 2004 Jan;1(1):27-42 [16305368.001]
  • (PMID = 17429576.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Neoplasm
  •  go-up   go-down


41. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol; 2009 Apr;174(4):1149-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
  • IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%).
  • Similarly, high frequencies of IDH1 mutations were found in oligodendrogliomas (79%) and oligoastrocytomas (94%).
  • IDH1 mutations were co-present with TP53 mutations in 63% of low-grade diffuse astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas; they were rare in pilocytic astrocytomas (10%) and primary glioblastomas (5%) and absent in ependymomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / genetics. Female. Humans. Male. Middle Aged. Mutation. Polymorphism, Single-Stranded Conformational. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Hum Genet. 1985;71(1):37-40 [3861566.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • (PMID = 19246647.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ PMC2671348
  •  go-up   go-down


42. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol; 2009 Dec 10;27(35):5874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anaplastic oligodendrogliomas and oligoastrocytomas share the same, better prognosis than anaplastic astrocytomas.
  • Hypermethylation of the O(6)-methylguanine DNA-methyltransferase (MGMT) promoter (HR = 0.59; 95% CI, 0.36 to 1.0), mutations of the isocitrate dehydrogenase (IDH1) gene (HR = 0.48; 95% CI, 0.29 to 0.77), and oligodendroglial histology (HR = 0.33; 95% CI, 0.2 to 0.55) reduced the risk of progression.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Isocitrate Dehydrogenase / genetics. Kaplan-Meier Estimate. Lomustine / administration & dosage. Lomustine / adverse effects. Male. Middle Aged. Mutation. Procarbazine / administration & dosage. Procarbazine / adverse effects. Promoter Regions, Genetic. Proportional Hazards Models. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. Risk Factors. Time Factors. Treatment Failure. Tumor Suppressor Proteins / genetics. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Dec 10;27(35):5861-2 [19901101.001]
  • [ErratumIn] J Clin Oncol. 2010 Feb 1;28(4):708
  • (PMID = 19901110.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
  •  go-up   go-down


43. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C: Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain; 2006 Jul;129(Pt 7):1884-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
  • Oligodendroglial neoplasms with the -1p/-19q genotype are more indolent with longer survival and increased therapeutic responsiveness than those with intact 1p/19q, but the biological basis for these clinical differences is unclear.
  • Recent research suggests that oligodendrogliomas with and without the -1p/-19q genotype may be distinguished by their magnetic resonance imaging (MRI) appearance, suggesting possible differences in growth characteristics.
  • This study examined the relationship between genotype and histological growth patterns of oligodendroglial neoplasms in association with MR imaging characteristics.
  • Thirty-three oligodendrogliomas (25 with 1p/19q loss) and 53 oligoastrocytomas (18 with 1p/19q loss) were investigated.
  • Solid, mixed or infiltrative growth patterns were seen in grade II and grade III tumours with or without 1p/19q loss, but infiltrative growth was more common in tumours with intact 1p/19q (chi2: P = 0.029).
  • Grade III tumours were more likely to have a solid growth pattern (chi2: P = 0.046) associated with contrast enhancement (chi2: P = 0.011).
  • This study identified a group of oligodendroglial tumours with intact 1p/19q displaying distinctive MR imaging features that were unrelated to the histopathology characteristics.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Allelic Imbalance. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Genotype. Humans. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670176.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Vital AL, Tabernero MD, Crespo I, Rebelo O, Tão H, Gomes F, Lopes MC, Orfao A: Intratumoral patterns of clonal evolution in gliomas. Neurogenetics; 2010 May;11(2):227-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we investigate the cytogenetic patterns of intratumoral clonal evolution of gliomas and their impact on tumor histopathology and patient survival.
  • Cytogenetic analysis of 90 gliomas was performed in individual tumor cells (>200 cells/tumor) using multicolor (N = 16 probes) interphase-FISH.
  • Virtually, all cases (99%) showed >or=2 tumor cell clones, with higher numbers among high- versus low-grade gliomas (p = 0.001).
  • Nine different cytogenetic patterns were found in the ancestral tumor clones.
  • Conversely, early tetraploidization was associated with low-grade astrocytomas-2/3 pilocytic and 3/6 grade II diffuse astrocytomas-and combined loss of 1p36/19q13 with oligodendrogliomas, respectively; both aberrations were associated with a better patient outcome (p = 0.03).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Male. Middle Aged. Survival Rate. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5268-72 [17000658.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Dec;61(12 ):1078-84 [12484570.001]
  • [Cites] Clin Neuropathol. 2005 Sep-Oct;24(5):209-18 [16167544.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Arch Pathol Lab Med. 2007 Oct;131(10):1585-90 [17922598.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86 [18617055.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Dec;59(12):1087-93 [11138928.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):201-11 [17569001.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] EMBO J. 2007 Nov 14;26(22):4683-93 [17948060.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):166-79 [15269292.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] J Cell Biochem. 2007 Dec 15;102(6):1368-74 [17972252.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4694-700 [9788624.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):353-60 [16391789.001]
  • [Cites] Neoplasma. 2007;54(4):334-41 [17822324.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] J Neurooncol. 2008 May;88(1):57-63 [18253699.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):673-80 [11562740.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4841-51 [14581356.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 1;180(1):14-9 [18068527.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Med Invest. 2004 Aug;51(3-4):146-53 [15460900.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jul;55(7):822-31 [8965097.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):595-604 [15497113.001]
  • [Cites] Curr Opin Genet Dev. 2007 Apr;17(2):157-62 [17324569.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):397-406 [17516742.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):10-20 [17319279.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):506-8 [11586105.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):413-6 [12543796.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):825-32 [15981281.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8 [17146292.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 15;351(2):336-9 [17067552.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):196-201 [11801559.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2897-905 [12019170.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):129-36 [17031656.001]
  • [Cites] J Neurosurg. 2002 May;96(5):815-22 [12005388.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Neoplasma. 2007;54(3):212-8 [17447852.001]
  • (PMID = 19760258.001).
  • [ISSN] 1364-6753
  • [Journal-full-title] Neurogenetics
  • [ISO-abbreviation] Neurogenetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Derlon JM, Cabal P, Blaizot X, Borha A, Chapon F: [Metabolic imaging for supratentorial oligodendrogliomas]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):309-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metabolic imaging for supratentorial oligodendrogliomas].
  • Only a few publications have yet reported its use in oligodendroglial tumors.
  • These findings and partial results obtained in ongoing work, suggest some preliminary conclusions: 11C-MET (L-methyl-methionine) is a more appropriate tracer than 18F-FDG (fluoro-deoxy-glucose), in terms of both specificity and sensitivity, for the assessment of patients with this category of tumor.
  • PET/MET allows differentiation between grade II and grade III oligodendrogliomas; better targeting for stereotactic biopsy; more accurate assessment of the post-operative residual tumor; identification of progression from low-grade to anaplastic grade during the disease course; differentiation between recurrence and a post-radiation processes.
  • [MeSH-major] Brain. Oligodendroglioma / metabolism. Positron-Emission Tomography. Supratentorial Neoplasms / metabolism
  • [MeSH-minor] Adult. Amino Acids / metabolism. Female. Glucose / metabolism. Glycolysis. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging. Male. Methionine / analogs & derivatives. Methionine / pharmacokinetics. Radioactive Tracers. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292175.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Radioactive Tracers; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester; IY9XDZ35W2 / Glucose
  •  go-up   go-down


46. Vesper J, Graf E, Wille C, Tilgner J, Trippel M, Nikkhah G, Ostertag C: Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. BMC Neurol; 2009;9:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
  • Although chemotherapy with procarbazine, lomustine and vincristine (PCV) is considered to be well tolerated, side effects frequently lead to dose reduction or even discontinuation of treatment of oligodendroglial brain tumors.
  • Based on the updated histology data, patients were included in the study if they had at least one histological diagnosis of an oligodendroglial tumor.
  • Significant advantages in terms of overall survival after first diagnosis of oligodendroglial tumor (OS, n = 315) were found for patients < 50 y (p < 0.001), oligodendrogliomas versus oligoastrocytomas (p = 0.002), and WHO degrees II vs. degrees III (p < 0.001).
  • Younger age, lower tumor grade and histology of an oligodendroglioma were identified to be favorable prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Lomustine / therapeutic use. Male. Middle Aged. Procarbazine / administration & dosage. Procarbazine / therapeutic use. Prognosis. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):705-10 [11723377.001]
  • [Cites] Acta Neurochir (Wien). 2001 Dec;143(12):1195-203 [11810382.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Dec;1(4):595-605 [12113092.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):231-7 [12241120.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):128-38 [12672285.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8 [14765381.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Oct;54(10):915-20 [1744647.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1809-15 [7880611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurosurg Rev. 1998;21(2-3):138-46 [9795948.001]
  • [Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):638-55 [15322700.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):257-65; discussion 257-65 [15670374.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1372-81 [16470609.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • (PMID = 19604414.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  • [Other-IDs] NLM/ PMC2719586
  •  go-up   go-down


47. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • In most analyses, WHO grade III and 1V tumors are not analyzed separately.
  • The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Scholz M, Lorenz A, Pesavento A, Brendel B, Khaled W, Engelhardt M, Pechlivanis I, Noack V, Harders A, Schmieder K: Current status of intraoperative real-time vibrography in neurosurgery. Ultraschall Med; 2007 Oct;28(5):493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to test the application of vibrography during brain tumor surgery.
  • MATERIALS AND METHODS: The real-time vibrography system consisted of a conventional ultrasound system (Siemens Sonoline Omnia) with a custom-designed RF interface and a 6.5-MHz endocavity curved array (Siemens 6.5EC10).
  • RESULTS: Brain tissue is normally color coded between red and orange.
  • In 4 cases tumors with strain values identical to those in brain tissue (coded red or orange) but easily identified by a peripheral zone of high strain (yellow) were found.
  • Tumors with strain values higher than those measured in brain tissue coded yellow and were softer than brain during surgical intervention.
  • In one patient minimal bleeding of the cortical surface occurred in a frontobasal tumor; however, no postoperative deficits were noted.
  • In low-grade astrocytomas and oligodendrogliomas, this additional technique can be used to control resection.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Monitoring, Intraoperative / methods. Neurosurgical Procedures. Ultrasonography, Interventional / methods
  • [MeSH-minor] Adult. Aged. Equipment Design. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed. Vibration

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17918047.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Zemanová Z, Kramar F, Babická L, Ransdorfová S, Melichercíková J, Hrabal P, Kozler P, Michalová K: Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH). Folia Biol (Praha); 2006;52(3):71-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH).
  • In oligodendroglial brain tumours, losses of chromosomal material of the short arm of chromosome 1 and long arm of chromosome 19 have been shown to predict responsiveness to chemotherapy and prolonged patients' survival.
  • Therefore, the correct diagnosis of these genetic alterations in tumours of oligodendroglial origin is particularly important.
  • To detect deletions of 1p36 and/or 19q13.3 in oligodendroglial cells we used dual-colour I-FISH with locus-specific DNA probes.
  • We examined 16 patients with histologically proved oligodendrogliomas (5x oligodendroglioma, 9x anaplastic oligodendroglioma, 2x anaplastic oligoastrocytoma).
  • However, in six of them additional genetic alterations typical for high-grade astrocytoma were found, which could have negative influence on the prognosis.
  • A systematic molecular cytogenetic analysis may advance diagnosis, prognostic stratification, and targeted treatment of patients with brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. In Situ Hybridization, Fluorescence. Interphase / physiology. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA Probes / metabolism. Female. Genome, Human / genetics. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089917.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


50. Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L, Silvani A, Bianchessi D, Broggi G, Boiardi A, Finocchiaro G: Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer; 2006 Jul 1;119(1):84-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligoastrocytomas (OAs) are WHO grade II or III tumors composed of a mixture of 2 neoplastic cell types morphologically resembling the cells in oligodendrogliomas and diffuse astrocytomas.
  • We have studied, in 94 OAs (46 WHO grade II and 48 WHO grade III), the patterns of loss of heterozygosity (LOH) of 4 genomic regions: 1p, 19q, 17p and 10q.
  • OAs without LOH on 1p behave like WHO grade II or III diffuse astrocytomas: they have shorter survival, MRI characteristics implying malignancy and genetic alterations associated with tumor progression.
  • OAs with LOH on 1p, on the other hand, behave like WHO grade II or III oligodendrogliomas with 1p loss: they are associated with longer survival and do not have MRI or genetic alterations associated with malignancy.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / genetics. Brain Neoplasms / classification. Brain Neoplasms / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Analysis of Variance. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 19. Disease Progression. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival Analysis


51. Calatozzolo C, Maderna E, Pollo B, Gelati M, Marras C, Silvani A, Croci D, Boiardi A, Salmaggi A: Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther; 2006 Jul;5(7):827-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas.
  • Both clinical and biological features have been reported as prognostic factors in low-grade gliomas.
  • Among these, histotype, tumor size, enhancement, age and genetic pattern.
  • Microvessel density (MVD) has been correlated to clinical outcome in astrocytomas, but its impact in oligodendrogliomas and mixed tumors is not sure.
  • The pro-angiogenic chemokine stromal cell-derived factor (SDF-1/CXCL12) and its receptor CXC chemokine receptor 4 (CXCR4) have been described in low-grade gliomas, with a correlation between CXCL12 expression and shorter time to progression (TTP).
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / diagnosis. Brain Neoplasms / blood supply. Brain Neoplasms / diagnosis. Chemokines, CXC / analysis. Neovascularization, Pathologic / diagnosis. Oligodendroglioma / blood supply. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Capillaries / pathology. Chemokine CXCL12. Female. Humans. Intermediate Filament Proteins / analysis. Male. Middle Aged. Nerve Tissue Proteins / analysis. Nestin. Prognosis. Proto-Oncogene Proteins c-sis / analysis. Receptor, Platelet-Derived Growth Factor beta / analysis. Receptors, CXCR4 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2006 Aug;5(8):1039-41 [16931903.001]
  • (PMID = 16760646.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, CXCR4; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


52. Wharton SB, Maltby E, Jellinek DA, Levy D, Atkey N, Hibberd S, Crimmins D, Stoeber K, Williams GH: Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol; 2007 Feb;113(2):119-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.
  • Oligodendrogliomas may be divided into those with deletion of chromosomes 1p and 19q (Del+), and those without (Del-).
  • Fluorescence in situ hybridisation with probes to 1p and 19q was used to determine the deletion status of 54 oligodendrogliomas, including WHO grades II and III.
  • Del+ oligodendrogliomas showed a higher apoptotic index than Del- tumours (P=0.037); this was not accounted for by differences in tumour grade or in proliferation.
  • There were no differences in the Mcm2-Ki67 index or in the geminin/Ki67 ratio between the subgroups, but grade III tumours showed a higher proportion of licensed non-proliferating cells than grade II tumours (P=0.001).
  • An increased susceptibility to apoptosis in oligodendrogliomas with 1p+/-19q deletion may be important in their improved clinical outcome compared to Del- tumours.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Cell Survival. Cytogenetics / methods. DNA Replication. Female. Humans. In Situ Hybridization, Fluorescence / methods. Ki-67 Antigen / metabolism. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):245-54 [15674481.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • [Cites] Histopathology. 2005 Mar;46(3):307-13 [15720416.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2827-43 [15838518.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):710-4 [15976337.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):455-66 [16150117.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):939-45 [16189522.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] Cell Death Differ. 2006 Jan;13(1):5-11 [16123777.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii115-23 [16760273.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):107-13 [11175741.001]
  • [Cites] Science. 2000 Dec 22;290(5500):2309-12 [11125146.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] J Pathol. 2001 Nov;195(4):457-62 [11745678.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] J Pathol. 2003 Feb;199(2):221-8 [12533835.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Arch Neurol. 1991 Feb;48(2):225-7 [1993014.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Hepatology. 1995 May;21(5):1465-8 [7737654.001]
  • [Cites] Neurosci Lett. 1995 Aug 4;195(2):81-4 [7478273.001]
  • [Cites] Neuropathol Appl Neurobiol. 1995 Aug;21(4):352-61 [7494604.001]
  • [Cites] Neurochem Int. 1997 Aug;31(2):245-50 [9220457.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Feb;24(1):21-8 [9549725.001]
  • [Cites] Cell. 1998 Jun 12;93(6):1043-53 [9635433.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Br J Neurosurg. 1998 Dec;12(6):539-46 [10070463.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • (PMID = 17160531.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC1781098
  •  go-up   go-down


53. Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R: Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol; 2009 Dec;22(12):1600-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
  • It is unclear how annexin-1 is expressed in various neuroepithelial tumors, and whether there is any association with tumor malignancy or survival.
  • We studied annexin-1 expression in 394 glial neoplasms of all grades of malignancy and 81 normal brain samples by immunohistochemistry using tissue microarrays.
  • In the normal human brain, the expression of annexin-1 is limited to ependymal cells and subependymal astrocytes, but is also upregulated in reactive astrocytes.
  • Ependymomas and astrocytomas showed significantly higher mean annexin-1 expression levels in the cytoplasm compared with oligodendrogliomas (both: P<0.0001).
  • In addition, nuclear staining of annexin-1 in oligodendroglial tumor cells was significantly reduced (P=0.0002), which may be used as a diagnostic tool for differentiating between astrocytomas and oligodendrogliomas.
  • Although annexin-1 expression in ependymomas decreased with the grade of malignancy, diffuse astrocytomas showed a significant increase in cytoplasmic annexin-1-positive tumor cells.
  • Thus, annexin-1 upregulation in astrocytomas may contribute to tumor progression and its expression profile is similar to its substrate, EGFR, suggesting a possible regulation thereof.
  • [MeSH-major] Annexin A1 / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Glioma / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / chemistry. Blotting, Western. Cell Nucleus / chemistry. Child. Child, Preschool. Ependymoma / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / chemistry. Prognosis. Receptor, Epidermal Growth Factor / analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Time Factors. Tissue Array Analysis. Young Adult


54. Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nistér M, Smits A, Ren ZP: Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol; 2007 Feb;113(2):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
  • Oligoastrocytomas are glial tumours consisting of a mixture of neoplastic astrocytic and oligodendroglial cells.
  • Genetic alterations of oligoastrocytomas include loss of heterozygosity of chromosomes 1p and/or 19q (LOH 1p/19q), typically occurring in oligodendrogliomas, and mutations of TP53, frequently occurring in astrocytomas.
  • In the majority of cases (9/11), the oligodendroglial and astrocytic components of an individual oligoastrocytoma displayed the same genotype.
  • In one case, the oligodendroglial part of the tumour showed LOH19q, whereas the astrocytic part showed TP53 mutation (codon 273).
  • In another case, we found LOH 1p/19q in the oligodendroglial component, but two retained areas on chromosome 1p in the astrocytic component of the tumour.
  • The two cases of biphasic oligoastrocytomas in our sample that display a different genotype in the astrocytic and oligodendroglial part of the tumour show that different components of an oligoastrocytoma may be derived from different cell clones during neoplastic transformation.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / genetics. Brain Neoplasms / classification. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Female. Humans. Male. Microsatellite Repeats. Middle Aged. Mutation. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031656.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


55. Rostomily RC, Born DE, Beyer RP, Jin J, Alvord EC Jr, Mikheev AM, Matthews RT, Pan C, Khorasani L, Sonnen JA, Montine TJ, Shi M, Zhang J: Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J Proteome Res; 2010 May 7;9(5):2610-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion.
  • Approximately 50-80% of oligodendrogliomas demonstrate a combined loss of chromosome 1p and 19q.
  • Although many hypotheses have been proposed, the molecular mechanisms underlying improved clinical outcomes with 1p/19q deletion in oligodendrogliomas have not been characterized fully.
  • To investigate the molecular differences between oligodendrogliomas, we employed an unbiased proteomic approach using microcapillary liquid chromatography mass spectrometry, along with a quantitative technique called isotope-coded affinity tags, on patient samples of grade II oligodendrogliomas.
  • Following conventional biochemical separation of pooled tumor tissue from five samples of undeleted and 1p/19q deleted grade II oligodendrogliomas into nuclei-, mitochondria-, and cytosol-enriched fractions, relative changes in protein abundance were quantified.
  • Among the 442 total proteins identified, 163 nonredundant proteins displayed significant changes in relative abundance in at least one of the three fractions between oligodendroglioma with and without 1p/19q deletion.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2009 Dec;95(3):343-54 [19597701.001]
  • [Cites] Am J Pathol. 2009 Jul;175(1):54-65 [19498008.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22695-703 [10801887.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Neurosci Methods. 2001 Aug 15;109(1):3-11 [11489294.001]
  • [Cites] Electrophoresis. 2002 Jan;23(2):311-28 [11840540.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Glia. 2003 Apr 15;42(2):194-208 [12655603.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6648-57 [14640741.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):53-8 [14756441.001]
  • [Cites] Brain Pathol. 2004 Jan;14(1):34-42 [14997935.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):39155-64 [15234983.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6696-700 [2208135.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Neurobiol Aging. 2005 Feb;26(2):207-27 [15582749.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Mar 24;134(1):119-38 [15790536.001]
  • [Cites] J Alzheimers Dis. 2005 Apr;7(2):125-33; discussion 173-80 [15851850.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):855-65 [15929038.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6726-33 [16061654.001]
  • [Cites] Acta Neuropathol. 2005 Sep;110(3):239-46 [16133547.001]
  • [Cites] Science. 2006 Apr 14;312(5771):212-7 [16614208.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Bioinformatics. 2006 Jul 1;22(13):1600-7 [16606683.001]
  • [Cites] Mol Cell Proteomics. 2006 Jul;5(7):1193-204 [16565515.001]
  • [Cites] J Alzheimers Dis. 2006 Aug;9(3):293-348 [16914840.001]
  • [Cites] Proteomics. 2007 Feb;7(3):469-73 [17211832.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Mol Cell Proteomics. 2007 Oct;6(10):1818-23 [17644759.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] Neoplasia. 2008 Feb;10(2):149-59 [18283337.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Feb;67(2):117-24 [18219256.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):261-72 [18398576.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):472-82 [18538731.001]
  • [Cites] Mol Cancer. 2008;7:41 [18492260.001]
  • [Cites] Neuropathology. 2008 Aug;28(4):382-6 [18298442.001]
  • [Cites] J Biol Chem. 2008 Sep 5;283(36):24848-59 [18611854.001]
  • [Cites] Neurology. 2009 Jan 13;72(2):156-61 [19139367.001]
  • [Cites] J Mol Med (Berl). 2009 Feb;87(2):153-67 [19066835.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • (PMID = 20337498.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007144; None / None / / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS0007144; United States / NINDS NIH HHS / NS / T32 NS007144-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS302192; NLM/ PMC3119493
  •  go-up   go-down


56. Coleman KE, Brat DJ, Cotsonis GA, Lawson D, Cohen C: Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance.
  • The authors assessed three techniques for quantitating MIB-1 (expression in oligodendrogliomas, correlating results with mitotic activity and prognosis.
  • Formalin-fixed, paraffin-embedded sections of 38 oligodendrogliomas were immunostained using monoclonal MIB-l.
  • MIB-1 expression and mitotic count were correlated with overall survival and recurrence (disease-free survival), defined clinically and radiographically as new tumor growth.
  • The authors show a significant correlation between MIB-1 PI using the visual method and recurrence in patients with oligodendrogliomas.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540741.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


57. Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven Vv, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lücking C, Zentner J, Ostertag C: The brain tumor board: lessons to be learned from an interdisciplinary conference. Onkologie; 2005 Jan;28(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The brain tumor board: lessons to be learned from an interdisciplinary conference.
  • BACKGROUND: The aim of this study is to analyze the work of the interdisciplinary Brain Tumor Board (BTB) which was established at Freiburg University Hospital in 1998.
  • This group was composed of 4 subgroups: 28% benign skull base tumors (19% meningiomas, 4% pituitary adenomas, 3% acoustic schwannomas, 2% others), 24% primary brain tumors of glial origin (8% glioblastomas, 12% gliomas other than glioblastomas, 5% oligoastrocytomas or oligodendrogliomas), 19% brain metastases, and 8% other brain or skull base tumors.
  • CONCLUSION: Interdisciplinary care seems to be particularly necessary in patients with benign skull base tumors, gliomas and brain metastases.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials Data Monitoring Committees / statistics & numerical data. Decision Support Systems, Clinical / statistics & numerical data. Outcome Assessment (Health Care). Patient Care Team / statistics & numerical data. Quality Assurance, Health Care / statistics & numerical data
  • [MeSH-minor] Academic Medical Centers / statistics & numerical data. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Germany / epidemiology. Humans. Male. Middle Aged. Practice Patterns, Physicians' / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15616378.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


58. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F: Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol; 2010 Mar;97(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas.
  • The aim of our study was to evaluate the role of proton magnetic resonance (MR) spectroscopy and MR perfusion in the follow-up of low-grade gliomas, since conventional MR imaging (MRI) is not reliable in detecting the passage from a low- to high-grade tumor.
  • Twenty-one patients with a World Health Organisation (WHO) grade II glioma were followed up using proton MR spectroscopy, perfusion, and conventional MRIs.
  • The mean annual growth of low-grade glioma was 3.65 mm.
  • Proton magnetic resonance spectroscopy should be recommended in the follow-up of low-grade gliomas since the choline/creatine ratio can predict anaplastic transformation before perfusion abnormalities, with high positive predictive value of 83%.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Cerebrovascular Circulation / physiology. Choline / metabolism. Contrast Media. Creatine / metabolism. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Protons. ROC Curve. Regional Blood Flow

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2007 Jan;188(1):204-12 [17179366.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):784-90 [15814921.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Nov;29(10):1872-7 [18719036.001]
  • [Cites] Radiology. 2008 Apr;247(1):170-8 [18372467.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):660-6 [17432719.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):458-63 [18065512.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] Radiologe. 2007 Sep;47(9):812-8 [16924439.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):74-81 [12546355.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]
  • [Cites] J Neurooncol. 2009 May;92(3):317-35 [19357959.001]
  • [Cites] Life Sci. 1996;58(22):1929-35 [8637421.001]
  • [Cites] Neuroradiology. 2005 Dec;47(12):887-91 [16133483.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):947-9 [12297589.001]
  • [Cites] Ann Neurol. 2003 Apr;53(4):524-8 [12666121.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]
  • [Cites] J Neurosci. 1993 Mar;13(3):981-9 [8441018.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Ann Neurol. 2006 Sep;60(3):380-3 [16983683.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):823-9 [11564242.001]
  • [Cites] Neurol Res. 2009 Nov;31(9):931-9 [19215664.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):688-93 [18184842.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] Eur Neurol. 2007;58(4):198-209 [17823533.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):516-24 [9322842.001]
  • (PMID = 19727562.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


59. Ferrer-Luna R, Mata M, Núñez L, Calvar J, Dasí F, Arias E, Piquer J, Cerdá-Nicolás M, Taratuto AL, Sevlever G, Celda B, Martinetto H: Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol; 2009 Dec;95(3):343-354
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.
  • Oligodendroglial tumors presenting loss of heterozygosity (LOH) at 1p and 19q have been shown to be sensitive to chemotherapy, thus making 1p-19q status testing a key aspect in oligodendroglioma diagnosis and prognosis.
  • Twenty-nine tumor samples (19 oligodendrogliomas, 10 oligoastrocytomas) were analyzed in order to obtain a molecular profile identifying those bearing 1p-19q LOH.
  • This molecular signature was validated by analyzing a set of ten tumor samples (three oligodendrogliomas, seven oligoastrocytomas); all ten samples were correctly assigned.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Expression Regulation, Neoplastic. Loss of Heterozygosity. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child, Preschool. Chromosome Deletion. Cluster Analysis. Gene Expression Profiling. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction


60. Jenkinson MD, du Plessis DG, Smith TS, Brodbelt AR, Joyce KA, Walker C: Cellularity and apparent diffusion coefficient in oligodendroglial tumours characterized by genotype. J Neurooncol; 2010 Feb;96(3):385-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellularity and apparent diffusion coefficient in oligodendroglial tumours characterized by genotype.
  • Previous studies report a negative linear correlation between minimum ADC and tumour cellularity in different types of gliomas, but there are no studies in oligodendroglial tumours.
  • This study evaluated the relationship between ADC and tumour cellularity in oligodendroglial tumours characterized by genotype.
  • METHODS: ADC was assessed in 17 patients with known 1p/19q status: 3 grade II oligodendrogliomas (OII), 9 grade II oligoastrocytomas (OAII), 5 grade III oligoastrocytomas (OAIII).
  • Grade III tumours had higher maximum cell density than grade II tumours (17.2 vs. 10.57%: Mann Whitney U; P = 0.20).
  • Oligoastrocytoma were more likely to have a lower minimum cell density than oligodendrogliomas (Mann Whitney U; P = 0.032).
  • CONCLUSIONS: In oligodendroglial tumours there is no relationship between quantitative assessment of cellularity and ADC.
  • This may reflect differences in oligodendroglial tumour biology compared to other gliomas, although the composition of the extracellular matrix may influence ADC more than cellularity.
  • [MeSH-major] Brain Neoplasms / pathology. Chromosomes, Human, Pair 1. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Diffusion Magnetic Resonance Imaging. Female. Genotype. Humans. Loss of Heterozygosity. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):56-61; discussion 61 [15639528.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7182-91 [15534091.001]
  • [Cites] J Magn Reson Imaging. 2007 Dec;26(6):1405-12 [17968881.001]
  • [Cites] Brain. 2006 Jul;129(Pt 7):1884-91 [16670176.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] NMR Biomed. 2007 Feb;20(1):49-57 [16986106.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] Neuroradiology. 2002 Aug;44(8):656-66 [12185543.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36 [11121466.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jul;181(1):235-41 [12818866.001]
  • [Cites] Neuroradiology. 2006 Oct;48(10):703-13 [16937145.001]
  • [Cites] Neurology. 2006 Jun 13;66(11):1661-7 [16769937.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):274-8 [15709124.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1424-31 [17031404.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4303-6 [15240515.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):855-65 [15929038.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):478-88 [16897692.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1081-8 [11415902.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9 [14970018.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] Neuroradiology. 2004 Aug;46(8):619-27 [15243726.001]
  • [Cites] Radiology. 2006 Sep;240(3):803-10 [16926329.001]
  • (PMID = 19618117.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. De Armas R, Durand K, Guillaudeau A, Weinbreck N, Robert S, Moreau JJ, Caire F, Acosta G, Pebet M, Chaunavel A, Marin B, Labrousse F, Denizot Y: mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas. Clin Biochem; 2010 Jul;43(10-11):827-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gliomas are tumors of the central nervous system derived from glial cells.
  • Although a possible role for the eicosanoid cascade has been suggested in glioma tumorigenesis, the relationship between enzymes and receptors implicated in arachidonic acid metabolism, with histological tumor type has not yet been determined.
  • DESIGN AND METHODS: Quantitative real-time reverse transcription-polymerase chain reaction was performed to measure and compare transcript levels of enzymes and receptors implicated in both lipoxygenase and cyclooxygenase pathways between oligodendrogliomas, astrocytomas, glioblastomas and mixed oligoastrocytomas.
  • RESULTS: Arachidonic acid metabolism-related enzymes and receptor transcripts (i) were underexpressed in classical oligodendrogliomas compared to astrocytomas and/or glioblastomas, (ii) differed between astrocytomas and glioblastomas and (iii) had an intermediate expression in mixed oligoastrocytomas.
  • [MeSH-major] Arachidonic Acid / metabolism. Central Nervous System Neoplasms / metabolism. Glioma / metabolism. Lipoxygenase / genetics. Prostaglandin-Endoperoxide Synthases / genetics. RNA, Messenger / analysis. Receptors, Prostaglandin / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20382140.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Prostaglandin; 27YG812J1I / Arachidonic Acid; EC 1.13.11.12 / Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


62. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res; 2005 Jan 1;11(1):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
  • Anderson Cancer Center since 1986 to include 72 glioblastomas, 49 anaplastic astrocytomas, 9 low-grade astrocytoma, 37 oligodendrogliomas, 37 anaplastic oligodendrogliomas, 15 mixed oligoastrocytomas, 20 anaplastic mixed oligoastrocytomas, and 7 gliosarcomas.
  • The microarray included normal brain tissue, and AP-2alpha expression was determined by immunohistochemistry.
  • RESULTS: AP-2alpha expression was lost on 99% (P < 0.001) and 98% (P < 0.001) of glioblastomas and anaplastic astrocytomas, respectively, compared with grade 2 astrocytomas and normal brain, all of which (100%) maintained expression of AP-2alpha.
  • However, there was no significant effect of loss of AP-2alpha expression on survival observed after adjustment for patient age, Karnofsky Performance Scale score, tumor grade, and extent of resection (rate ratio, 1.2; 95% confidence interval, 0.6-2.2; P = 0.6).
  • CONCLUSIONS: AP-2alpha expression correlates inversely with glioma grade, suggesting a direct role in glioma tumorigenicity, possibly through subsequent deregulation of target genes.
  • Of all the previously characterized markers of progression, the loss of AP-2alpha would be the most common (96.2%) molecular marker as an astrocytic tumor evolves from grade 2 to 3.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / physiology. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Transcription Factors / biosynthesis. Transcription Factors / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Motifs. Antigens, CD / biosynthesis. Antigens, CD146. Astrocytoma / metabolism. Brain / metabolism. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p21. Disease Progression. Humans. Immunohistochemistry. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Neural Cell Adhesion Molecules / biosynthesis. Oligodendroglioma / metabolism. Oligonucleotide Array Sequence Analysis. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-kit / biosynthesis. Time Factors. Transcription Factor AP-2. Treatment Outcome. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / T-32-09666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / MCAM protein, human; 0 / Neural Cell Adhesion Molecules; 0 / TFAP2A protein, human; 0 / Transcription Factor AP-2; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


63. Sunyach MP, Jouvet A, Perol D, Jouanneau E, Guyotat J, Gignoux L, Carrie C, Frappaz D: Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol; 2007 Dec;85(3):319-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of exclusive chemotherapy as first line treatment in oligodendroglioma.
  • PURPOSE: The optimal therapy of oligodendrogliomas remains uncertain.
  • METHODS AND MATERIALS: Among 89 patients treated for oligodendrogliomas at the Centre Léon Bérard of Lyon from 1982 to 1999, 59 patients fitted inclusion criteria, having had centrally reviewed pure oligodendroglioma requiring treatment.
  • According to the WHO's classification 35 patients had Grade III and 24, Grade II oligodendrogliomas.
  • CONCLUSION: Front-line exclusive chemotherapy results in prolonged OS in patients with confirmed pure oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Frontal Lobe / pathology. Humans. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Feb;86(3):361-2 [17710374.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Neurology. 1996 Jan;46(1):203-7 [8559376.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1902-9 [10023313.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):567-73 [7928487.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):959-66; discussion 966 [8084406.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2179-88 [3440228.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] J Neurooncol. 1995;24(1):3-7 [8523071.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):170-5 [10776979.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):802-9 [15637687.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E15 [16398465.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):22-9 [2049748.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4002-6 [8508366.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Ann Neurol. 1990 May;27(5):573-4 [2360797.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1978;17(6):475-84 [216238.001]
  • [Cites] Recent Results Cancer Res. 1994;135:127-33 [8047688.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S73-83 [12915906.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2519-24 [12829670.001]
  • [Cites] Neurology. 2003 Apr 8;60(7):1113-8 [12682316.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Qual Life Res. 2002 Feb;11(1):37-45 [12003054.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2473-6 [16270316.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):399-403 [9069313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Neurosurg. 1987 Aug;67(2):224-30 [3598683.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 17568995.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP: Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol; 2005 Feb;26(2):266-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.
  • BACKGROUND AND PURPOSE: Histopathologic evaluation remains the reference standard for diagnosis of glioma and classification of histologic subtypes, but is challenged by subjective criteria, tissue sampling error, and lack of specific tumor markers.
  • The purpose of our study was to investigate dynamic susceptibility contrast-enhanced (DSC) MR imaging characteristics of the two most common subtypes of low-grade infiltrating glioma: astrocytoma and oligodendroglioma.
  • We hypothesized that tumor blood-volume measurements, derived from DSC MR imaging, would help differentiate the two on the basis of differences in tumor vascularity.
  • METHODS: We studied 25 consecutive patients with treatment-naive, histopathologically confirmed World Health Organization grade II astrocytoma (n = 11) or oligodendroglioma (n = 14).
  • RESULTS: The maximum relative CBV (rCBV(max)) in tumor ranged from 0.48 to 1.34 (0.92 +/- 0.27, median +/- SD) in astrocytomas and from 1.29 to 9.24 (3.68 +/- 2.39) in oligodendrogliomas.
  • The difference in median rCBV(max) between the two tumor types was significant (P < .0001).
  • CONCLUSION: The tumor rCBV(max) measurements derived from DSC MR imaging were significantly higher in low-grade oligodendrogliomas than in astrocytomas.
  • Our findings suggest that tumor rCBV(max) derived from DSC MR imaging can be used to distinguish between the two low-grade gliomas.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Blood Volume. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709123.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS 45013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


65. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA: Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res; 2005 Dec 15;65(24):11335-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles associated with treatment response in oligodendrogliomas.
  • Oligodendrogliomas are a specific subtype of brain tumor of which the majority responds favorably to chemotherapy.
  • In this study, we made use of expression profiling to identify chemosensitive oligodendroglial tumors.
  • Because transcripts associated with chemotherapeutic response were identified independent of common chromosomal aberrations, expression profiling may be used as an alternative approach to the tumors' 1p status to identify chemosensitive oligodendroglial tumors.
  • The observation that many genes are differentially expressed between long and short survivors indicates that the genetic background of the tumor is an important factor in determining the prognosis of the patient.
  • Our study is the first to correlate gene expression with chromosomal aberrations and clinical performance (response to treatment and survival) in oligodendrogliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Loss of Heterozygosity. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357140.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


66. Durand KS, Guillaudeau A, Weinbreck N, DeArmas R, Robert S, Chaunavel A, Pommepuy I, Bourthoumieu S, Caire F, Sturtz FG, Labrousse FJ: 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis. Mod Pathol; 2010 Apr;23(4):619-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In glial tumors, the loss of heterozygosity of the 1p and 19q chromosomal arms is thought to be a marker of good prognosis in oligodendroglial tumors.
  • However, 1p and 19q loss of heterozygosity may be telomeric, interstitial, centromeric or affect the whole arm of the chromosome and the associations between these different patterns and tumor type, other molecular markers and patient prognosis remain unclear.
  • We analyzed microsatellite markers in a region spanning the chromosome from the telomere to the centromere, to characterize the pattern of 1p and 19q loss of heterozygosity in 39 infiltrative gliomas, including astrocytomas, glioblastomas, oligoastrocytomas and oligodendrogliomas.
  • 1p19q whole loss was present in all the classical oligodendrogliomas, whereas other 1p19q loss patterns predominated in oligoastrocytomas.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioma / genetics. Nerve Tissue Proteins / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Polymerase Chain Reaction. Prognosis. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20081802.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


67. Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, Renault-Mihara F, Thirant C, Leonard N, Berhneim A, Mihalescu-Maingot M, Haiech J, Bièche I, Moura-Neto V, Daumas-Duport C, Junier MP, Chneiweiss H: CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer; 2010;10:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors.
  • BACKGROUND: Tumor initiating cells (TICs) provide a new paradigm for developing original therapeutic strategies.
  • METHODS: We screened for TICs in 47 human adult brain malignant tumors.
  • Cells forming floating spheres in culture, and endowed with all of the features expected from tumor cells with stem-like properties were obtained from glioblastomas, medulloblastoma but not oligodendrogliomas.
  • Xenografts of fewer than 500 cells in Nude mouse brains induced a progressively growing tumor.
  • CONCLUSIONS: Our results further highlight the specificity of a subset of high-grade gliomas, MGNT.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD15 / biosynthesis. Antigens, CD34 / biosynthesis. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Glycoproteins / biosynthesis. Neoplastic Stem Cells / cytology. Neurons / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Peptides. Proteomics / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2006 Jan;111(1):29-38 [16320026.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):961-73 [17204602.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2695-706 [17057735.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2897-904 [17504989.001]
  • [Cites] PLoS One. 2008;3(11):e3655 [18985161.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):440-52 [19427293.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2373-82 [19544474.001]
  • [Cites] Prog Neurobiol. 2000 Dec;62(5):443-73 [10869779.001]
  • [Cites] Ann Pathol. 2000 Oct;20(5):413-28 [11084409.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1652-8 [11245479.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):289-96 [11718261.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Trends Neurosci. 2004 Mar;27(3):148-54 [15036880.001]
  • [Cites] Nature. 2004 Jul 15;430(6997):350-6 [15254537.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Neurosurgery. 2004 Dec;55(6):1377-91: discussion 1391-2 [15574220.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • (PMID = 20181261.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, CD34; 0 / Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2841664
  •  go-up   go-down


68. White ML, Zhang Y, Kirby P, Ryken TC: Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol; 2005 Apr;26(4):784-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?
  • BACKGROUND AND PURPOSE: The association of high-grade oligodendrogliomas with tumor contrast material enhancement on MR images has been reported.
  • Some authors have even used contrast enhancement as a criterion for their oligodendroglioma grading system.
  • The purpose of our study was to evaluate if tumor contrast enhancement is a specific finding for anaplastic oligodendroglioma.
  • METHODS: Pretreatment MR images of 24 oligodendrogliomas were reviewed retrospectively, and findings were compared with the histologic grade.
  • The presence or absence and the pattern of tumor contrast enhancement were evaluated qualitatively.
  • A contrast enhancement ratio (CER), a quantitative criterion, was calculated to assess the difference in degree of enhancement between the low-grade and anaplastic tumors.
  • Tumor grade was diagnosed at pathologic examination according to the World Health Organization classification system.
  • RESULTS: Contrast enhancement was noted in nine (56%) of 16 low-grade tumors and in five (62%) of eight anaplastic tumors.
  • The CERs were 2.12-40.88 (mean, 20.08) in low-grade tumors and were 3.20-62.52 (mean, 28.73) in anaplastic tumors (P > .05).
  • CONCLUSION: Tumor contrast enhancement was not statistically significantly different between the tumor groups.
  • We believe that the presence or absence of tumor contrast enhancement is not a specific finding for simply discriminating low-grade from anaplastic oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814921.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol; 2009 Apr;11(2):167-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
  • The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA).
  • Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation.
  • The worst nonhematological toxicity was grade 4 in three patients (8%).
  • There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose Fractionation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Survival Rate. Treatment Outcome. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):271-8 [14558604.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • (PMID = 18779504.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2718988
  •  go-up   go-down


70. Larysz D, Blamek S, Larysz P, Pietras K, Mandera M: Posterior fossa brain tissue injury: developmental, neuropsychological, and neurological consequences of brain tumors in children. Acta Neurochir Suppl; 2010;106:271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior fossa brain tissue injury: developmental, neuropsychological, and neurological consequences of brain tumors in children.
  • The aim of the study was the functional neurodevelopmental assessment of children with posterior fossa tumors, specifically examining whether tumor location in particular cerebellar structures determines particular neuropsychological deficits.
  • There were 21 total and 8 subtotal resections of tumor, and marsupialization was performed in cases of arachnoid cysts.
  • Histopathological diagnoses of tumors were as follows: 4 medulloblastomas, 8 pilocytic astrocytomas, 6 fibrillary astrocytomas, 1 anaplastic astrocytoma, 2 oligodendrogliomas, 4 anaplastic ependymomas, 1 choroid plexus papilloma, and 5 arachnoid cysts.
  • [MeSH-major] Brain. Brain Injuries / etiology. Cognition Disorders / etiology. Infratentorial Neoplasms. Nervous System Diseases / etiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Functional Laterality / physiology. Humans. Male. Neuropsychological Tests. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812963.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


71. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol; 2008 Oct 1;26(28):4659-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
  • PATIENTS AND METHODS: This was a single-arm, phase II study.
  • Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A).

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92 [12604685.001]
  • [Cites] Curr Biol. 2001 Feb 20;11(4):232-41 [11250151.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1732-4 [14630677.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Nature. 1983 Jun 2-8;303(5916):390-6 [6304520.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):381-9 [8106574.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):771-6 [9815748.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] Clin Pharmacol Ther. 2006 Aug;80(2):192-201 [16890580.001]
  • [Cites] Oncogene. 2006 Aug 10;25(35):4913-22 [16547494.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):432-8 [17312388.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):864-73; discussion 873-4 [11322447.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Ann Oncol. 2002 May;13(5):777-80 [12075748.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1348-50 [12091065.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503 [10850862.001]
  • (PMID = 18824712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC2653126
  •  go-up   go-down


72. Netto GC, Bleil CB, Hilbig A, Coutinho LM: Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology; 2008 Feb;28(1):17-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
  • The determinants of this process, the growth factors and the vascular endothelial receptors have brought a potential in the tumor prognostic determination as well as perspectives of "targets" for antiangiogenic therapy.
  • In oligodendrogliomas (OL), angiogenesis is little known and/or has generated conflicting results.
  • There was expression in <10% of tumor cells and/or staining of weak intensity in 15 (50.0%), >10% of cells and moderate intensity staining in 1 (3.33%), and negative expression in 14 (46.67%).
  • If present, the expression was restricted to tumor and endothelial cells.
  • The mean +/- SD MVD-CD105 and MVD-CD34 were 10.83 +/- 2.24 and 11.00 +/- 2.76 in OL (P = 0.086; r = 0.319); 10.00 +/- 2.00 and 10.40 +/- 3.02 in OL grade II (n = 15) (P = 0.547; r = 0.105), and 11.67 +/- 2.22 and 11.53 +/- 2.45 in OL grade III (n = 15) (P = 0.817; r = 0.551), respectively.
  • The absence of correlation between DMV-CD105, DMV-CD34 and tumor grades suggests that anti-CD105 and anti-CD34 antibodies have different vascular specificities.
  • MVD-CD105 was greater in OL grade III than in OL grade II (P = 0.0032), indicating an increase in the vascular neoformation, something which must be evaluated as a possible prognostic factor in OL.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD34 / biosynthesis. Brain Neoplasms / blood supply. Neovascularization, Pathologic / pathology. Oligodendroglioma / blood supply. Receptors, Cell Surface / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Endothelium, Vascular / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181830.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


73. Sherman JH, Prevedello DM, Shah L, Raghavan P, Pouratian N, Starke RM, Lopes MB, Shaffrey ME, Schiff D: MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien); 2010 Nov;152(11):1827-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
  • PURPOSE: Patients with oligodendrogliomas with allelic loss of chromosomal arm 1p and 19q have been shown, especially with anaplastic oligodendrogliomas, to have both a better initial and long-term response to chemotherapy as well as an improved overall survival.
  • Effective treatment of patients with brain tumors requires accurate diagnostic techniques.
  • MR imaging can be used to help differentiate between low- and high-grade tumors.
  • METHODS: Using the clinical database at the University of Virginia Neuro-Oncology Center, we identified adult patients with grade II and III oligodendroglial tumors who underwent treatment from 2002 to 2007.
  • Age at diagnosis, gender, tumor grade, chromosomal deletion status, duration of follow-up, and MR imaging characteristics were analyzed; the latter was read by a blinded neuroradiologist.
  • The greatest cross-sectional area (mean) of the tumor measured 23.4 cm(2) for patients with the co-deletion and 31.7 cm(2) for patients with intact alleles (p = 0.008).
  • Amongst patients with pure oligodendrogliomas, those with 1p/19q co-deletion had tumors more often confined to a single lobe as compared with those patients without the co-deletion (p = 0.023).
  • CONCLUSION: MR imaging is a valuable imaging modality for differentiating between oligodendrogliomas with or without the 1p/19q deletion.
  • While imaging will never replace definitive tissue diagnosis, imaging characteristics such as tumor size, location, and overlying skull thinning can assist clinicians in assessing patients with oligodendroglial tumors prior to surgical or medical intervention.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Deletion. Genetic Predisposition to Disease / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. DNA Mutational Analysis / methods. Disease Progression. Female. Genetic Testing / methods. Humans. Male


74. Hägerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Hartman M, Nistér M, Kalimo H, Ostman A: Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Neuro Oncol; 2008 Feb;10(1):2-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.
  • Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification.
  • To what extent the major histological subtypes - astrocytomas, oligodendrogliomas, and oligoastrocytomas - constitute true biological entities is largely unresolved.
  • In this study, 23 grade II gliomas were expression-profiled and subjected to hierarchical clustering.
  • All six oligodendrogliomas were grouped together in one of two major clusters; a significant correlation was thus observed between gene expression and histopathological subtype.
  • Supervised analyses were performed to identify genes differentiating oligodendrogliomas from other grade II tumors.
  • The expression of the rPTP beta/zeta protein in oligodendrogliomas and astrocytomas was further validated by immunohistochemistry in an independent set of tumors.
  • All 11 oligodendrogliomas of this set displayed strong staining.
  • In summary, this study demonstrates a correlation between gene expression pattern and histological subtype in grade II gliomas.
  • Furthermore, the results from the immunohistochemical analyses of rPTPbeta/zeta expression should prompt further evaluation of this protein as a novel oligodendroglioma marker.

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):635-40 [11148662.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):411-4 [12355066.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1462-9 [12424117.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6661-8 [14555979.001]
  • [Cites] Expert Opin Ther Targets. 2004 Jun;8(3):211-20 [15161428.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Bioinformatics. 2004 Jul 22;20(11):1797-8 [14988123.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):6012-22 [15208679.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Curr Opin Neurobiol. 1998 Feb;8(1):117-27 [9568399.001]
  • [Cites] Lab Invest. 1998 May;78(5):643-4 [9605190.001]
  • [Cites] J Cell Biol. 1998 Jul 13;142(1):203-16 [9660874.001]
  • [Cites] Bioessays. 1998 Jun;20(6):463-72 [9699458.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Sep 18;60(1):77-88 [9748513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] J Neurooncol. 1999 May;42(3):259-69 [10433109.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2271-8 [16489031.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • (PMID = 18003890.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  • [Other-IDs] NLM/ PMC2600835
  •  go-up   go-down


75. Molinari C, Iorio P, Medri L, Ballardini M, Guiducci G, Cremonini AM, Cerasoli S, Riccioni L, Faedi M, Mariani GA, Zoli W, Silvestrini R, Calistri D: Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study. Int J Mol Med; 2010 Jan;25(1):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.
  • Oligodendrogliomas are rare primary brain tumors with variable patient outcomes which are not always adequately accounted for by clinical or pathological variables.
  • The present study evaluated the prognostic implications of chromosome 1p and 19q status in a set of 23 low grade oligodendrogliomas (OGD II), and correlated the results with patient outcome.
  • Our results showed that the molecular alterations are associated with age and tumor localization.
  • Further studies are now ongoing to determine whether this methodological approach could be potentially useful in low grade oligodendrogliomas to better characterize chromosomal alterations of 1p/19q and identify subgroups of patients with a higher risk of disease recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Deletion. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956913.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


76. Levidou G, Korkolopoulou P, Agrogiannis G, Paidakakos N, Bouramas D, Patsouris E: Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature. Diagn Pathol; 2010;5:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature.
  • BACKGROUND: Gliomas are a very rare subtype of pineal region tumours, whereas oligodendrogliomas of the pineal region are exceedingly rare, since there have been only 3 cases of anaplastic oligodedrogliomas reported this far.
  • METHODS-RESULTS: We present a case of a low-grade oligodendroglioma arising in the pineal gland of a 37 year-old woman.
  • Total resection was performed and histological examination showed that the cystic wall consisted of tumour cells with a central nucleus a perinuclear halo and minimal pleomorphism.
  • However, the diagnosis of a low grade oligodendroglioma of the pineal gland was assigned.
  • CONCLUSION: Although the spectrum of tumours arising in the pineal gland is broad, the reports of oligodendrogliomas confined to this location are exceedingly rare, and to the best of our knowledge there is no report of a low-grade oligodendroglioma.
  • [MeSH-major] Oligodendroglioma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Proliferation. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neoplasm Staging

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1983 Jul;42(4):391-408 [6864234.001]
  • [Cites] J Morphol. 1982 Jul;173(1):73-86 [7108968.001]
  • [Cites] Surg Neurol. 1985 Feb;23(2):139-42 [3966205.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):20-30 [7821912.001]
  • [Cites] Surg Neurol. 1995 Jan;43(1):70-5; discussion 75-6 [7701429.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Brain Res. 1999 Sep 25;842(2):359-75 [10526132.001]
  • [Cites] Prog Brain Res. 1965;10:193-217 [14281603.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):80-6 [15662708.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Pathol Res Pract. 2006;202(2):85-92 [16413691.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):461-4 [16961143.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):307-14 [16645719.001]
  • [Cites] Minim Invasive Neurosurg. 2006 Aug;49(4):247-50 [17041839.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Clin Neuropathol. 2008 May-Jun;27(3):118-28 [18552083.001]
  • [Cites] J Pineal Res. 1984;1(4):323-37 [6545825.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):49-60 [10668895.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 May;40(5):283-6 [11980097.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):223-8 [12691627.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):99-103 [7006792.001]
  • [Cites] Pediatrics. 1984 Jul;74(1):97-102 [6739222.001]
  • (PMID = 20849631.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2949720
  •  go-up   go-down


77. Vergani F, Sanson M, Duffau H: Combined multiple surgical intervention and chemotherapy for multicentric WHO grade II glioma : a long-term follow-up study. Acta Neurochir (Wien); 2009 Dec;151(12):1699-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multiple surgical intervention and chemotherapy for multicentric WHO grade II glioma : a long-term follow-up study.
  • BACKGROUND: Multicentric WHO grade II gliomas constitute a rare entity.
  • OBJECTIVE: We present a 23 year-old female with two synchronous but separate WHO grade II oligodendrogliomas in the temporal and frontal lobes.
  • On the basis of our results, we suggest that an active therapeutic strategy, by combining multiple surgical procedures and complementary treatment, should be systematically considered in multicentric WHO grade II gliomas, as in similar unifocal neoplasms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Oligodendroglioma / drug therapy. Oligodendroglioma / surgery
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415180.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


78. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res; 2005 Feb 1;11(3):1119-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
  • PURPOSE: Allelic loss at 1p is seen in 70% to 85% of oligodendrogliomas (typically in association with 19q allelic loss) and 20-30% of astrocytomas.
  • Because most 1p deletions in gliomas involve almost the entire chromosome arm, narrowing the region of the putative tumor suppressor gene has been difficult.
  • The latter group included both low-grade tumors (oligodendroglioma, diffuse astrocytoma, and "oligoastrocytoma") and high-grade tumors (anaplastic oligodendrogliomas, anaplastic astrocytomas, anaplastic oligoastrocytomas).
  • RESULTS: Allelic losses on 1p and 19q, either separately or combined, were more common in classic oligodendrogliomas than in either astrocytomas or oligoastrocytomas (P < 0.0001).
  • Classic oligodendrogliomas showed 1p loss in 35 of 42 (83%) cases, 19q loss in 28 of 39 (72%), and these were combined in 27 of 39 (69%) cases.
  • There was no significant difference in 1p/19q LOH status between low-grade and anaplastic oligodendrogliomas.
  • Although rare, 1p deletions were more often segmental in astrocytomas (5 of 6, 83%) than in oligodendrogliomas (3 of 35, 9%; P = 0.006).
  • Eleven tumors (6 oligodendrogliomas or having oligodendroglial components, 5 purely astrocytic) with small segmental 1p losses underwent further detailed LOH mapping.
  • All informative tumors in the oligodendroglial group and 2 of 3 informative astrocytomas showed LOH at 1p36.23, with a 150-kb MDR located between D1S2694 and D1S2666, entirely within the CAMTA1 transcription factor gene.
  • CAMTA1 is normally expressed predominantly in non-neoplastic adult brain tissue.
  • Relative to the latter, the expression level of CAMTA1 was low in oligodendroglial tumors and was further halved in cases with 1p deletion compared with those without 1p deletion (Mann-Whitney, P = 0.03).
  • CONCLUSIONS: Our data confirm the strong association of combined 1p/19q loss with classic oligodendroglioma histology and identify a very small segment of 1p36 located within CAMTA1 that was deleted in all oligodendroglial tumors with 1p LOH.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Calcium-Binding Proteins / genetics. Chromosome Deletion. Chromosome Mapping. Expressed Sequence Tags. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Microsatellite Repeats. Mutation. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709179.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMTA1 protein, human; 0 / Calcium-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


79. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D: Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol; 2007 Jul;9(3):271-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
  • Glioblastoma multiforme (GBM) can present as either de novo or secondary tumors arising from previously diagnosed low-grade gliomas.
  • Although these tumor types are phenotypically indistinguishable, de novo and secondary GBMs are associated with distinct genetic characteristics.
  • PTEN mutations, which result in activation of the phosphoinositide 3-kinase (PI3K) signal transduction pathway, are frequent in de novo but not in secondary GBMs or their antecedent low-grade tumors.
  • Results we present here show that grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas commonly display methylation of the PTEN promoter, a finding that is absent in nontumor brain specimens and rare in de novo GBMs.
  • Our results also demonstrate frequent methylation of the PTEN promoter in grade III astrocytomas and secondary GBMs, consistent with the hypothesis that these tumors arise from lower grade precursors.
  • PTEN methylation is rare in de novo GBMs and is mutually exclusive with PTEN mutations.
  • We conclude that methylation of the PTEN promoter may represent an alternate mechanism by which PI3K signaling is increased in grade II and III gliomas as well as secondary GBMs, a finding that offers new therapeutic approaches in these patients.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6546-52 [16818626.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):621-7 [15196854.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50 [9560261.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2447-54 [9796977.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3005-10 [9865913.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1100-6 [12006525.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1178-84 [12006535.001]
  • [Cites] Cancer Cell. 2002 May;1(4):299-305 [12086841.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):74-80 [12203792.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Drugs R D. 2003;4(3):179-84 [12757405.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2000-6 [15026336.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207(2):215-20 [15072831.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Front Biosci. 2000 Jan 1;5:D213-31 [10702383.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):2057-64 [11062168.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):89-94 [11083071.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):22-6 [11149415.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):32-8 [11190805.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):493-7 [11179477.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):900-2 [11221878.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8571-80 [15467756.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):357-63 [15891996.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):768-76 [16084946.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Thyroid. 2006 Jan;16(1):17-23 [16487009.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):29-41 [11237521.001]
  • (PMID = 17504928.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA97257; United States / NCI NIH HHS / CA / R01 CA52689; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA082783-06; United States / NCI NIH HHS / CA / R01 CA082783; United States / NCI NIH HHS / CA / CA082783-06; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1907411
  •  go-up   go-down


80. Vogazianou AP, Chan R, Bäcklund LM, Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP, Ichimura K: Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol; 2010 Jul;12(7):664-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the status of chromosomes 1 and 19 in 363 astrocytic and oligodendroglial tumors.
  • Whereas the predominant pattern of copy number abnormality was a concurrent loss of the entire 1p and 19q regions (total 1p/19q loss) among oligodendroglial tumors and partial deletions of 1p and/or 19q in astrocytic tumors, a subset of apparently astrocytic tumors also had total 1p/19q loss.
  • The presence of total 1p/19q loss was associated with longer survival of patients with all types of adult gliomas independent of age and diagnosis (P = .041).
  • Novel regions of homozygous deletion, including a part of DPYD (1p21.3) or the KLK cluster (19q13.33), were observed in anaplastic oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / diagnosis. Glioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Nat Rev Neurosci. 2006 Feb;7(2):93-102 [16429119.001]
  • [Cites] Nature. 2006 May 18;441(7091):315-21 [16710414.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9428-36 [17018597.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):82-91 [16556484.001]
  • [Cites] Nat Rev Immunol. 2007 Apr;7(4):255-66 [17380156.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] PLoS One. 2007;2(6):e576 [17593975.001]
  • [Cites] J Appl Genet. 2007;48(3):261-8 [17666779.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):363-70 [17610521.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4705-12 [11156223.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4100-8 [12124348.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):97-112 [12203773.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):476-87 [12600941.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7600-5 [14633674.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):529-35 [15057824.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):182-3 [15172758.001]
  • [Cites] J Neurooncol. 1995;23(3):249-52 [7673988.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2503-10 [18302158.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):355-64 [18394558.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18255-60 [19017811.001]
  • [Cites] PLoS One. 2009;4(1):e4107 [19119320.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):458-65 [19147558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3420-5 [19223589.001]
  • [Cites] Cancer Sci. 2009 May;100(5):920-6 [19445024.001]
  • [Cites] Brain Pathol. 1999 Oct;9(4):639-43 [10517502.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):638-55 [15322700.001]
  • (PMID = 20164239.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618; United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2940668
  •  go-up   go-down


81. Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, Matsuo M: 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol; 2009 Nov-Dec;28(6):445-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated 5-LO expression and examined whether the 5-LO pathway is associated with the proliferation of human brain tumors.
  • METHODS: We immunohistochemically evaluated the profile of 5-LO expression in various types of brain tumors obtained from 42 patients, and examined the proliferative effects of the 5-LO pathway in human glioma cell lines using a proliferation assay.
  • RESULTS: Immunohistochemistry of glioblastomas, astrocytomas, meningiomas, medulloblastomas, craniopharyngiomas, ependymomas, neurinomas, oligodendrogliomas, malignant lymphomas, dysembryoplastic neuroepithelial and metastatic brain tumors revealed 5-LO expression in the cytoplasm and nuclei or nuclear envelopes of tumor cells.
  • CONCLUSIONS: We confirmed the expression of 5-LO in various human brain tumors and demonstrated the partial suppression of tumor growth by inhibitors of the 5-LO-LTA4 hydrolase pathway in human glioma cell lines.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / physiology. Brain Neoplasms / pathology. Cell Proliferation. Glioma / pathology. Signal Transduction / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / physiopathology. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Glioblastoma / pathology. Glioblastoma / physiopathology. Humans. Leucine / analogs & derivatives. Leucine / pharmacology. Leukotriene A4 / antagonists & inhibitors. Leukotriene A4 / physiology. Lipoxygenase Inhibitors. Male. Meningioma / pathology. Meningioma / physiopathology. Middle Aged. Protease Inhibitors / pharmacology. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919819.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Leukotriene A4; 0 / Lipoxygenase Inhibitors; 0 / Protease Inhibitors; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; GMW67QNF9C / Leucine; I0J33N5627 / ubenimex
  •  go-up   go-down


82. Plesec TP, Prayson RA: Frozen section discrepancy in the evaluation of central nervous system tumors. Arch Pathol Lab Med; 2007 Oct;131(10):1532-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen section discrepancy in the evaluation of central nervous system tumors.
  • CONTEXT: Frozen section (FS) evaluation of central nervous system (CNS) lesions provides an assessment of specimen adequacy and facilitates triage for ancillary studies.
  • DESIGN: All CNS FS cases involving a tumor diagnosis at FS or permanent section (N = 2156) from September 1997 until June 2005 were retrospectively reviewed.
  • Twelve (21.1%) of 57 cases involved errors in differentiating oligodendrogliomas from astrocytomas.
  • Nine (15.8%) of 57 discrepancies involved errors in the diagnosis of CNS lymphoma.
  • CONCLUSIONS: Frozen section of CNS neoplastic processes can be highly accurate.
  • Approximately 80% of the discrepant cases were classified into 5 categories: spindle cell lesions, astrocytoma versus oligodendroglioma, differential diagnosis of CNS lymphoma, reactive versus neoplastic process, and tumor overgrading.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Errors / statistics & numerical data. Frozen Sections / methods. Pathology, Surgical / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922589.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY: Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology; 2009 May 5;72(18):1601-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
  • BACKGROUND: Treatment with a regimen of bevacizumab-irinotecan has been shown to be effective in recurrent grade 3 and 4 gliomas, but the effect of this regimen against recurrent oligodendroglial tumors has not been specifically studied.
  • METHODS: The bevacizumab-irinotecan regimen was retrospectively evaluated in a consecutive series of 25 patients with recurrent oligodendroglial tumors.
  • CONCLUSIONS: This regimen is effective in recurrent oligodendrogliomas, and the overall tolerance is acceptable.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Bevacizumab. Cerebral Hemorrhage / epidemiology. DNA Mutational Analysis. Female. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Male. Middle Aged. Patient Compliance. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2010 Jan 12;74(2):181 [20065257.001]
  • (PMID = 19414728.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


84. Pinto GR, Yoshioka FK, Silva RL, Clara CA, Santos MJ, Almeida JR, Burbano RR, Rey JA, Casartelli C: Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res; 2008;7(1):207-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TP53 tumor suppressor gene codifies a protein responsible for preventing cells with genetic damage from growing and dividing by blocking cell growth or apoptosis pathways.
  • Aiming to study the role of TP53 Pro47Ser and Arg72Pro on glioma susceptibility and oncologic prognosis of patients, we investigated the genotype distribution of these SNPs in 94 gliomas (81 astrocytomas, 8 ependymomas and 5 oligodendrogliomas) and in 100 healthy subjects by the polymerase chain reaction-restriction fragment length polymorphism approach.
  • [MeSH-major] Glioma / genetics. Polymorphism, Single Nucleotide. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / genetics. Brazil. Case-Control Studies. Child. Child, Preschool. Female. Gene Frequency. Genes, p53. Genetic Predisposition to Disease. Genotype. Humans. Infant. Male. Middle Aged. Prognosis. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393224.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


85. Nataf F, Koziak M, Ricci AC, Varlet P, Devaux B, Beuvon F, Roujeau T, Page P, Cioloca C, Turak B, Schlienger M, Touboul E, Haie-Meder C, Vannetzel JM, Dhermain F, Honnorat J, Jouvet A, De Saint-Pierre G, Daumas-Duport C, Bret P, Roux FX: [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):329-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults].
  • [Transliterated title] Résultats de la série Sainte-Anne - Lyon de 318 oligodendrogliomes intracrâniens de l'adulte.
  • INTRODUCTION: Incidence of cerebral oligodendrogliomas is increasing because of better recognition made possible by improved classifications.
  • PATIENTS AND METHODS: A retrospective series of 318 adult patients with oligodendroglioma (OLG) treated at Hôpital Sainte-Anne, Paris (SA) and Hôpital Neurologique, Lyons (L) between 1984 and 2003 was analyzed: 182 grade A OLG (SA + L), 136 grade B among which a homogenous series of 98 (SA) were included.
  • For grade A: age at diagnosis ranged from 21 to 70 (mean: 41), sex ratio was 1.28.
  • For grade B: age at diagnosis ranged from 12 to 75 (mean: 45.5), sex-ratio was 1.58.
  • The most frequent locations were: frontal, insular and central for both A and B.
  • Mean size was 55 mm for grade A, 62 mm for B.
  • No tumor was enhanced on imaging (CT/MRI) in grade A, all but 7 in grade B.
  • Radiotherapy was performed in 76.9% of grade A, and 91% of B patients, in the immediate postoperative period for 71% A and 82.7% B.
  • Chemotherapy was delivered for 36% of grade A (in the event of transformation to grade B or failure of radiotherapy) and 67.5% of B patients.
  • Among grade A tumors, 38% transformed into grade B within a mean delay of 51 months with a mean follow-up of 78 months.
  • RESULTS: Median survival was 136 months for grade A and 52 for grade B.
  • Survival at 5, 10 and 15 was 75.5%, 51% and 22.4% for grade A vs 45.2%, 31.3% and 0% for grade B respectively.
  • In univariate and multivariate analysis, grade A survival was associated with age at diagnosis, tumor size, large removal and response to radiotherapy.
  • Grade B survival was associated with age at diagnosis, wide removal and sharply defined limits of the tumor on imaging.
  • It shows that OLG are heterogeneous tumors even in each grade (A and B).
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Staging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Epilepsy / diagnosis. Epilepsy / etiology. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292177.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


86. Okamoto H, Li J, Gläsker S, Vortmeyer AO, Jaffe H, Robison RA, Bogler O, Mikkelsen T, Lubensky IA, Oldfield EH, Zhuang Z: Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol Ther; 2007 Mar;6(3):391-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic comparison of oligodendrogliomas with and without 1pLOH.
  • Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity.
  • METHODS: In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling.
  • RESULTS: We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH.
  • CONCLUSIONS: These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosomes, Human, Pair 1 / genetics. Drug Resistance, Neoplasm / genetics. Loss of Heterozygosity. Neoplasm Proteins / analysis. Oligodendroglioma / metabolism. Proteome / genetics
  • [MeSH-minor] Adult. Aged. Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Middle Aged. Proteomics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264672.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095809-04; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


87. Stockhammer F, von Deimling A, Synowitz M, Blechschmidt C, van Landeghem FK: Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. J Mol Histol; 2008 Oct;39(5):553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II.
  • Objective Oligodendroglial tumors with a loss of heterozygosity of 1p (LOH1p) appear to have a better prognosis than oligodendrogliomas without LOH.
  • Previously, we reported glucose uptake in low-grade oligodendroglial tumors to be related to LOH 1p status.
  • Material and methods We examined 17 oligodendrogliomas (O II, 11 with LOH1p), 16 oligoastrocytomas (OA II, 5 with LOH1p) and 7 astrocytomas (A II, none with LOH1p).
  • Results Confocal microscopy depicted immunoreaction for GLUT-1, -3 and -12 in the cytoplasm of the tumor cells.
  • Oligodendrogliomas revealed a lower immunoreactivity for GLUT-1 than oligoastrocytomas and astrocytomas (P = 0.0263).
  • Conclusion Expression of GLUT-1 is significantly reduced in low-grade oligodendroglial tumors harboring LOH 1p.
  • Further studies should address the functional role of GLUT-1 in regard to chemosensitivity of oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosomes, Human, Pair 1 / metabolism. Glioma / metabolism. Glucose Transporter Type 1 / biosynthesis. Loss of Heterozygosity
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic / genetics. Glucose Transport Proteins, Facilitative / biosynthesis. Glucose Transport Proteins, Facilitative / genetics. Glucose Transporter Type 3 / biosynthesis. Glucose Transporter Type 3 / genetics. Humans. Male. Microscopy, Confocal / methods. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Protein p53 / genetics